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Abstract 
Renalase is a secretory protein that may protect against hypertension by reducing levels of 
circulating catecholamines (CAs). Renalase knockout mice are hypertensive with elevated CA 
levels. There are no known physiological mechanisms that fully describe renalase’s influence on 
plasma CAs. The adrenal medulla is a major site for CA regulation, however, the role of renalase 
in this tissue has not been investigated. The purpose of this study was to determine a potential role 
of renalase in this tissue using three objectives: 1) Examine the regulation of renalase by signal 
activators of CA biosynthesis; 2) Determine the effects of renalase on the regulation of CA-
biosynthesizing enzymes; 3) Examine the expression of renalase in hypertensive rats. For objective 
1, renalase expression was analyzed in pheochromocytoma-derived PC12 cells after treatment with 
10 signal activators (e.g. phorbol 12-myristate 13-acetate (PMA), forskolin, cobalt chloride 
(CoCl2), and dexamethasone (Dex)). For objective 2, PC12 cells were treated with recombinant 
renalase and mRNA levels of CA-biosynthesizing enzymes were quantitated. For objective 3, 
renalase expression was examined in adrenal glands from spontaneously hypertensive rats (SHRs) 
and compared with normotensive Wistar-Kyoto rats (WKYs). RT-PCR and western blotting were 
performed to quantify mRNA and protein levels. Three signal activators significantly altered 
renalase expression; changes in renalase expression were observed after PMA, CoCl2, and Dex 
treatment. Recombinant renalase treatment did not change the expression of CA-biosynthesizing 
enzymes. SHRs compared to WKYs had significantly higher levels of renalase mRNA, but not 
protein. Overall, this study is a first step to determine if renalase’s role in the adrenal medulla is to 
regulate CA biosynthesis and protect against hypertension. 
Keywords: Renalase, catecholamine biosynthesis, adrenal medulla, PC12 cells, hypertension, 
spontaneously hypertensive rat (SHR) 
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1 – Introduction 
1.1 – Overview 
Catecholamine (CA) regulation is an important physiological process that can be used to 
help explain the complex etiologies of hypertension. Patients with hypertension, when compared 
with normotensive individuals, commonly have altered CA regulatory processes throughout the 
body, resulting in higher levels of CAs in the blood (Currie, Freel, Perry, & Dominiczak, 2012; 
Goldstein, 1983). The CAs adrenaline and noradrenaline are potent vasoconstrictors, which is why 
they are regulated by several intricate mechanisms of homeostatic control (Guimarães & Moura, 
2001; Kumer & Vrana, 1996). Many of these regulatory mechanisms have not been fully 
characterized and it is likely that there are others still to be discovered.  
One example of a potentially novel regulator of CAs is the protein, renalase. Renalase 
knockout (KO) mice have elevated plasma CA levels, lower body mass, higher blood pressure 
(BP), and tachycardia (Y. Wu et al., 2011). Additionally, recombinant renalase administration can 
decrease systolic and diastolic BP for up to 24 hours (Desir, Tang, et al., 2012). Nevertheless, there 
are no complete explanations for renalase’s regulation of BP and CA levels. Therefore, the 
following review will serve to summarize the current understanding of the physiological 
connections between hypertension, CAs, and renalase.  
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1.2 – The Relationship Between Catecholamines and Hypertension 
1.2.1 – Modern Issues of Hypertension on Human Health  
 Hypertension, or high BP, is frequently described as one of the biggest medical challenges 
of the twenty-first century. This disease is defined as a systolic and/or diastolic BP greater than or 
equal to 140mmHg and 90mmHg, respectively (J. A. Whitworth & World Health Organization, 
International Society of Hypertension Writing Group, 2003). One major medical issue of 
hypertension is the positive correlation between BP and the risk of developing various diseases 
such as cardiovascular disease (CVD), renal disease, Alzheimer disease, gout, and age-related 
maculopathy (Carretero & Oparil, 2000; Kivipelto et al., 2002; Roubenoff et al., 1991; Sperduto 
& Hiller, 1986). In 2010, it was estimated that hypertension affects 1.39 billion people, or 31.1% 
of the adult human population (Mills et al., 2016). Considering the health care expenditures in 
developed countries, it is surprising to know that 22.6% of adult Canadians were reported to have 
hypertension in 2013 (Padwal, Bienek, McAlister, & Campbell, 2016). A reason for this finding 
is that approximately 95% of cases of hypertension have unknown causes (Cowley, 2006). Such 
cases are named essential hypertension (also known as primary/idiopathic hypertension), while 
cases with known causes are named secondary hypertension (Carretero & Oparil, 2000). When 
considering a cause of hypertension, there are countless potential dysregulations of BP, carried out 
via genetic mutations and/or environmental factors, and they have required the use of many 
categories of anti-hypertensive medications. These include diuretics, angiotensin-converting 
enzyme (ACE) inhibitors, calcium-channel blockers (CCBs), angiotensin type-1 receptor blockers 
(ARBs), β-blockers, and several other groups that are less-commonly used (Weber et al., 2014). 
The cost of these medications, along with the cost of hospitalizations, physician claims, and 
ambulatory care, were approximated to be $13.9 billion in 2010 for Canada alone, thus placing a 
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large burden on the overall economy (Weaver et al., 2015). Despite our current efforts to treat 
hypertension, studies have estimated 10-30% of cases are categorized as resistant hypertension 
(Calhoun et al., 2008; Viera, 2012; Yaxley & Thambar, 2015). Resistant hypertension is defined 
as BP that remains above a treatment goal, under the condition that the patient has tried three 
different classifications of anti-hypertensive medications concurrently (Calhoun et al., 2008). 
Taken together, essential and resistant hypertension reveal that our understanding of this disease 
is limited. Considering the high risk, prevalence, and cost of hypertension, researching new 
pathophysiological mechanisms of hypertension remains an important component of healthcare. 
A key to revealing these mechanisms is to increase our understanding of BP homeostasis. 
1.2.2 – Understanding Blood Pressure Regulation 
The magnitude of one’s BP can be generalized as relating to two hemodynamic factors: 
cardiac output (CO) and vascular resistance (Cowley, 2006). CO is defined as the volume of blood 
pumped by the left or right heart in a specific time, while vascular resistance is a measurement of 
the resistance of blood flow through the systemic or pulmonary circulations (Bigatello & George, 
2002). Many physiological variables are known to influence CO and/or vascular resistance such 
as heart rate (chronotropic effects), cardiac contractility (inotropic effects), blood and interstitial 
fluid volumes, arterial and venous diameters, blood viscosity, and vascular compliance (Bigatello 
& George, 2002; Eisner, Caldwell, Kistamás, & Trafford, 2017; Forconi, Wild, Munzel, & Gori, 
2011; A. Y. Hwang, Dietrich, Pepine, & Smith, 2017). Interactions between these variables and 
BP are summarized in Figure 1. In this figure, it is demonstrated that the regulation of these 
variables is a responsibility that is shared across multiple organs and tissues.  
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Figure 1: Flow chart of blood pressure regulation. Measurements of blood pressure are attained 
from the product of cardiac output (CO) and vascular resistance. Renal, nervous, or endocrine 
tissues regulate both physiological factors directly or indirectly via cross-talk between tissue types. 
Dashed lines indicate inhibition from negative feedback mechanisms. Image is modified from 
Cowley, 2006. 
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The nervous system uses several communication mechanisms that alter BP. Such 
mechanisms include the activities of the sympathetic and parasympathetic nervous systems. 
Sympathetic efferent fibers innervate the heart, blood vessels, adrenal medulla, and kidney 
(Chopra, Baby, & Jacob, 2011; Guyenet, 2006). In these tissues, they release norepinephrine (NE) 
or acetylcholine (ACh) from post-ganglionic terminals as a signal to increase BP (Purves et al., 
2001). On the other hand, parasympathetic efferent fibers innervate the heart and only release ACh 
from post-ganglionic terminals as a signal to decrease BP (Guyenet, 2006; Purves et al., 2001). 
The action to either increase or decrease BP is partly determined by continuous afferent sensory 
signaling from baroreceptors and chemoreceptors. The baroreceptors sense changes in BP and 
intra-renal pressure and are found in various areas across the cardiovascular system (e.g. the carotid 
sinus and aortic arch) and the kidney (Guyenet, 2006; Kougias, Weakley, Yao, Lin, & Chen, 2010). 
Chemoreceptors are located in the carotid artery and kidney and sense changes in O2, CO2, or 
particular ion concentrations (Booth, May, & Yao, 2015; Purves et al., 2001). Other areas of the 
nervous system, especially the hypothalamus, can create indirect effects on BP by regulating the 
release of hormones (Ayada, Toru, & Korkut, 2015). 
The kidney is another vital regulator of BP. Its actions consist of blood volume control, 
renin-angiotensin-aldosterone system (RAAS) activation, and electrolyte homeostasis (Wadei & 
Textor, 2012). The kidney receives signals to perform these actions from sympathetic nerves, the 
RAAS, and the pituitary hormone, anti-diuretic hormone (ADH) (Johns, 2013). Nephrons are 
capable of self-regulation by sensing components in the blood and filtrate by the juxtaglomerular 
complex, tubules, and collecting duct (CD) (Wadei & Textor, 2012). Blood volume control is 
mainly carried out through changes in the glomerular filtration rate (GFR), afferent arteriole 
vasoconstriction, and water reabsorption (Johns, 2013). These changes influence BP through a 
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direct relationship between CO and blood volume (Cowley, 2006). RAAS activation is initiated 
by juxtaglomerular cells with the secretion of renin (Atlas, 2007). Renin secretion is a necessary 
step to the formation of angiotensin II (Ang II) and subsequently, aldosterone, which together 
increase BP through numerous system-wide effects (Atlas, 2007). Additionally, the role of 
electrolyte reabsorption can be considered as a major influence on BP as there are many studies 
showing a positive correlation between blood concentrations of electrolytes (usually sodium – 
Na+) and BP (Jones, 2004). These correlations are not fully understood because of the general 
involvement of electrolytes in most physiological mechanisms across the body. However, they can 
be partially explained by the notion that salt increases blood volume and left ventricular mass 
(Meneton, Jeunemaitre, de Wardener, & Macgregor, 2005). 
 Myriad other contributions to BP regulation come from the endocrine system. These 
contributions involve the traditional endocrine glands, as well as tissues with specialized endocrine 
function. Regarding sex hormones, there is evidence that estrogens can decrease BP in several 
ways, including a direct signaling action on the vasculature to elicit vasodilation (Dubey, Oparil, 
Imthurn, & Jackson, 2002). Further, the thyroid hormone, triiodothyronine (T3), can induce 
increased systolic BP when T3 is high, or increased diastolic BP when T3 is low (Danzi & Klein, 
2003). A notable tissue with specialized endocrine function is the endothelium. This tissue can 
sense variable conditions in the blood and consequently secrete vasoconstrictive peptides, such as 
endothelins (ETs), or vasodilatory compounds, such as prostaglandins (PGs), nitric oxide (NO), 
adenosine, C-type natriuretic peptide (CNP), and endothelium-derived factors (Inagami, Naruse, 
& Hoover, 1995). The adrenal glands reputably create stress-related BP changes by producing 
steroids (e.g. aldosterone and cortisol) and the CAs, epinephrine (Epi), and NE (Ayada et al., 
2015). Two important neuroendocrine mechanisms for stress-related changes in BP are the 
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hypothalamic-pituitary-adrenal (HPA) axis and sympatho-adrenal (SA) axis, which results in 
cortisol (a glucocorticoid) and CA secretion into circulation, respectively (Ayada et al., 2015). In 
this research project, it is this process of CA regulation that will be focused on in further detail.  
 While these physiological mechanisms are effective at controlling BP, there are countless 
environmental and genetic factors that disturb this homeostasis. For example, Mendelian 
inheritance can enhance or reduce the activity of candidate genes for hypertension. Genes with 
mutations that alter their activity include sodium reabsorption genes (e.g. aldosterone synthase and 
the epithelial Na+ channel – ENaC) and RAS genes (e.g. angiotensinogen – AGT, and ACE; 
Jeunemaitre et al., 1992; Lifton, Gharavi, & Geller, 2001). Millions of single nucleotide 
polymorphisms (SNPs) have been associated with high or low BP too (Delles, McBride, Graham, 
Padmanabhan, & Dominiczak, 2010). SNPs have been identified in genes responsible for calcium 
channels (e.g. plasma membrane calcium channel 1 – PMCA1), steroid-biosynthesizing enzymes 
(e.g. cytochrome P450 17A1), and transcription factors (TFs) involved in the cardiovascular 
differentiation process (Delles et al., 2010). Many gender differences in BP regulation exist, 
indicating the importance of X and Y-linked genes. It is likely that this finding is partly due to the 
effect of estrogens and possibly, androgens (Reckelhoff, 2001). With regard to one’s environment, 
diet, exercise, and drug use are all contributing factors to BP. For example, consumption rates of 
electrolytes (e.g. magnesium – Mg2+, potassium – K+, calcium – Ca2+, and Na+), fiber, and 
antioxidants (e.g. polyphenols) can all affect BP (Hügel, Jackson, May, Zhang, & Xue, 2016). 
Exercise can alter BP over long periods of time by protecting against left ventricular hypertrophy 
and by modulating lipid profiles to decrease vascular resistance (Kannan et al., 2014; Lou, Zong, 
& Wang, 2017). Drugs can affect many areas of BP regulation, such as sympathetic activation by 
nicotine and endothelial function by alcohol (Husain, Ansari, & Ferder, 2014; Pickering, 2001). 
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Over time, collective effects of environmental factors usually lead to increased BP with age (Lifton 
et al., 2001). Environmental effects start as early as the fetal development stage in utero. 
Environmental influences like diet and stress can change the expression levels of BP-regulating 
genes in offspring and eventually lead to adult hypertension (Barker et al., 1993; Tain et al., 2014). 
Finally, these genetic and environmental factors are a large reason why mRNA and protein levels 
are commonly upregulated or downregulated in hypertensive patients and animals. Another area 
of BP regulation that is commonly altered by such influences is CA regulation. We will now see 
why alterations in CA regulation can have large effects on many physiological systems and BP. 
1.2.3 – The Physiological Effects of Catecholamines 
The CAs, dopamine (DA), Epi, and NE, each have their own set of signaling roles across 
the body. Epi and NE bind to adrenoceptors while DA binds to dopaminergic receptors. These 
receptors are further divided into subclassifications with independent signaling mechanisms. The 
expression pattern of CA receptors is largely tissue-dependent, allowing for CAs to have unique 
effects on specialized cell-types. Because CAs are localized in the circulation, nervous tissue, and 
interstitial tissues, their physiological effects are expansive and difficult to fully characterize. 
Dopaminergic activation is carried out through two types of receptors: D1-like receptors 
(D1Rs) and D2-like receptors (D2Rs). D1Rs consist of D1 and D5 receptors and interact with Gs 
to activate adenylate cyclase (AC), protein kinase A (PKA), and Ca2+ release from endoplasmic 
reticulum stores (Missale, Nash, Robinson, Jaber, & Caron, 1998). The D2Rs consist of D2, D3, 
and D4 receptors and provide opposite effects via Gi interaction and AC inhibition (Missale et al., 
1998). 
The effects of DA mainly apply to nervous, endocrine, and cardiovascular systems. In the 
nervous system, central neurons, especially in the limbic system, use DA as a neurotransmitter 
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(Nieoullon, 2002). The dopaminergic neural pathways typically have a role in memory, emotion, 
learning, attention, and motor function (Nieoullon, 2002). In the kidney, DA is synthesized and 
secreted by tubule cells of the nephron (mostly in proximal tubules; M. R. Lee, 1993). Here, DA 
usually signals for increased natriuresis and diuresis via regulation of transporters such as the 
sodium-proton exchanger (NHE; Bobulescu et al., 2010). Both D1Rs and D2Rs can be 
differentially expressed in the tubules and CDs, making the effects of DA largely dependent on 
the prevalence of each receptor (Missale et al., 1998). Moreover, D2Rs are present in the pituitary 
gland and adrenal gland, allowing for DA to inhibit the secretion of certain hormones like 
prolactin, melanocyte-stimulating hormone, aldosterone, and CAs (as a feedback mechanism; 
Baek, Seo, & Lim, 2008; Fitzgerald & Dinan, 2008; McKenna, Island, Nicholson, & Liddle, 1979; 
Missale et al., 1998). DA also increases RAAS activity (via D1Rs of juxtaglomerular cells), but 
also modifies RAAS’s effect by inhibiting aldosterone and various Ang II receptors (Gildea, 2009; 
McKenna et al., 1979; Missale et al., 1998). In the cardiovascular system, the localization of DA 
receptors in the tunica media of various arteries (e.g. in the renal, femoral, coronary, and 
mesenteric arteries) results in an overall effect of vasodilation (Amenta, Ricci, Tayebati, & 
Zaccheo, 2002). In contrast, highly concentrated DA in the blood can increase CO by a specialized 
DA binding pattern in the heart (Clark & Menninger, 1980). Therefore, the effect of circulating 
DA is usually a decrease in BP, but in exceptional cases, an increase in BP can be observed.  
Adrenergic receptors are grouped into two categories: α and β receptors (Guimarães & 
Moura, 2001). α receptors can be further divided into α1 and α2 receptors, each with different 
signaling activities (Guimarães & Moura, 2001). α1, α2, and β receptors have three additional 
subtypes, all having high affinities to NE and Epi, with the exception of the β2 subtype, which has 
a low affinity for NE (Molinoff, 1984). Like DA receptors, adrenergic receptors are all coupled to 
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G proteins. Generally, α1 receptors activate protein kinase C (PKC), α2 receptors inhibit PKA, and 
β receptors activate PKA (Tank & Lee Wong, 2015). 
The effects of NE and Epi are usually summarized as a mediator of the “fight-or-flight” 
response. This response is an evolutionary tactic used to temporarily combat or evade predators. 
NE and Epi are localized in the central nervous system (CNS), where part of their function is to 
learn and memorize stressful events (Tank & Lee Wong, 2015). α1 receptors are found in smooth 
muscles of the eye and vasculature and their stimulation contracts muscles by increasing Ca2+ in 
the cytosol (Guimarães & Moura, 2001). Tubular cells can have α1 receptors, which leads to 
increased sodium reabsorption during stimulation (Ritz, Amann, & Fliser, 1998). α2 receptors, on 
the other hand, are expressed in presynaptic terminals of post-ganglionic neurons and inhibit AC 
activation to reduce the effect of excess NE during neurotransmission (Giovannitti, Thoms, 
Crawford, & Crawford, 2015). Another inhibitory action of α2 receptors occurs in the islets of 
Langerhans; stimulation of α2 receptors can inhibit insulin secretion and reduce glucose 
storage/uptake from the blood (Hsu, Xiang, Rajan, & Boyd, 1991). Because chromaffin cells (the 
secretory cells of the adrenal medulla) are derived from post-ganglionic neurons, they also express 
α2 receptors, which may produce a negative feedback mechanism when CA secretion occurs 
(Moura, Afonso, Hein, & Vieira-Coelho, 2009). Regarding β receptors, β2 subtypes are 
vasodilatory in the vasculature, while β1 subtypes produce positive chronotropic and inotropic 
effects on the heart (Guimarães & Moura, 2001). This feature of subtype distribution creates a 
characteristic increase in blood flow to skeletal muscle and a decrease in blood flow to digestive 
organs. To add, specialized localization of the β receptors results in a concentration-dependent 
effect of Epi on BP (Tank & Lee Wong, 2015). Low concentrations of Epi activate β2 receptors, 
leading to vasodilation, thus lowering BP. With high concentrations of Epi, α1 receptor activation 
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predominates, leading to vasoconstriction and increased BP. NE’s low affinity for β2 receptors 
allows for it to increase BP at a range of concentrations. β receptors are present in adipocytes, the 
juxtaglomerular complex, and hepatocytes too (Erraji-Benchekroun et al., 2004; Louis, Jackman, 
Nero, Iakovidis, & Louis, 2000; Torretti, 1982). Hence, the “fight-or-flight” response is also 
known for increasing lipolysis, renin secretion, and glycogenolysis and gluconeogenesis.  
1.3 – Mechanisms of Catecholamine Regulation 
1.3.1 – Tissue-Specific Regulation of Catecholamines 
 The mechanisms of CA regulation are largely determined by their tissue localization. 
Tissues regulate CAs either by the rate of their synthesis, storage, secretion, or breakdown.  
The majority of CA biosynthesis occurs in the adrenal medulla and specialized neurons 
(Kvetnansky, Sabban, & Palkovits, 2009). To a limited degree, the kidney, heart, liver, immune 
cells, mesenteric organs, and other tissues may synthesize CAs (Armando, Villar, & Jose, 2011; 
Eisenhofer, Kopin, & Goldstein, 2004; Elayan, Kennedy, & Ziegler, 1990; Flierl, Rittirsch, Huber-
Lang, Sarma, & Ward, 2008; Peltsch et al., 2016; Uhlen et al., 2015; Ziegler, Bao, Kennedy, 
Joyner, & Enns, 2002). The CA biosynthesis pathway is a highly regulated process that can convert 
three amino acid precursors to any of the CAs using a system of five enzymes (Figure 2). 
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Figure 2: The catecholamine biosynthesis pathway. The five enzymes and cofactors are boxed in 
grey. Amino acid precursors are in the region highlighted in red and CAs are in the region 
highlighted in yellow. 
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The first step of this pathway is the conversion of L-phenylalanine (Phe) to L-tyrosine (Tyr) by 
the enzyme phenylalanine hydroxylase (PAH). This step is mostly performed by the liver, but there 
is evidence showing it can occur in CA-synthesizing tissues (Uhlen et al., 2015). Because Tyr can 
be consumed in the diet, PAH’s actions are not the rate-limiting step of CA synthesis. Instead, a 
rate-limiting step occurs with Tyr’s conversion to L-dihydroxyphenylalanine (DOPA) by tyrosine 
hydroxylase (TH; Kuhar, Couceyro, & Lambert, 1999a). As a rate-limiting enzyme, it is 
appropriate that many forms of regulation have evolved, including phosphorylation (e.g. Ser-40 
modification), allosteric binding, transcriptional regulation, and translational regulation (Kumer & 
Vrana, 1996). Both PAH and TH require oxygen, tetrahydrobiopterin (BH4), and iron for their 
enzymatic mechanisms (Flydal & Martinez, 2013; Kumer & Vrana, 1996). After this step, DA is 
produced from DOPA with the enzyme, aromatic L-amino acid decarboxylase (AADC), and its 
cofactor, pyridoxal phosphate (PLP). Evidence suggests that AADC does not have complex 
regulatory systems similar to TH (Waymire & Haycock, 2002). Next, DA can be hydroxylated to 
form NE by dopamine β-hydroxylase (DBH) and its cofactors, oxygen, copper, and ascorbate 
(Kvetnansky et al., 2009). Several regulatory mechanisms of DBH exist, many of which being 
tissue-dependent. Tissue-based regulation is important as it allows the secretory cells to release 
DA or NE, which have largely different physiological roles. One notable regulatory mechanism of 
DBH is the ability of cyclic adenosine monophosphate (cAMP) to increase the level of DBH gene 
transcription (O. Hwang & Joh, 1993). The last reaction of the biosynthesis pathway is the 
conversion of NE to Epi by phenylethanolamine N-methyltransferase (PNMT) and its cofactor, s-
adenosyl methionine (SAM; Kuhar et al., 1999a). Epi has different receptor affinities from NE and 
therefore, PNMT is also regulated by numerous mechanisms. Following the transcription of 
PNMT, two splicing variants are produced: intron-retaining and intronless mRNA (Unsworth, 
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Hayman, Carroll, & Lelkes, 1999). The intron-retaining mRNA contains an early stop codon and 
translates to an inactive form of PNMT (Wong, Tai, Wong-Faull, Claycomb, & Kvetnanský, 
2008). Increased transcriptional regulation of PNMT can alter the levels of intron-retaining 
mRNA, intronless mRNA, or both splice variants (Ansell, Grandbois, & Tai, 2014; Unsworth et 
al., 1999). In vivo studies of adrenal tissue suggest that intron-retention may be important for 
cellular differentiation, but its overall role is still unclear (Unsworth et al., 1999). A well-accepted 
regulatory mechanism of PNMT is the robust effect of glucocorticoids to decrease intron-retaining 
mRNA and increase intronless mRNA. Consequently, for tissues to synthesize CAs de novo, they 
require extracellular regulatory conditions to activate the biosynthesis enzymes, which is why CA 
synthesis is generally restricted to nervous and adrenal tissues. 
 Another form of CA regulation is to change the rate of CA uptake and storage into secretory 
vesicles. CA products must be transported to secretory vesicles because biosynthesis enzymes are 
mostly localized in the cytosol (the exception being DBH, which is found in secretory vesicles; 
Kuhar, Couceyro & Lambert, 1999b). CA uptake into secretory vesicles is performed by a family 
of H+-ATPase transporters known as vesicular monoamine transporters (VMATs). These 
transporters can be regulated transcriptionally and post-translationally via phosphorylation and 
protein-protein interactions (German, Baladi, McFadden, Hanson, & Fleckenstein, 2015). On the 
cell membrane of secretory cells, they express other CA transporters like norepinephrine 
transporters (NETs) and dopamine transporters (DATs; Uhlen et al., 2015). These transporters are 
important for reusing excess CAs in the cerebrospinal fluid (CSF), blood, and interstitial spaces. 
Studies have shown that these transporters may be downregulated by increased oxidative stress 
(Mao et al., 2004). Storage regulation is also highly dependent on the expression of chromogranins. 
Chromogranins are proteins important for the formation of secretory vesicles, the inhibition of 
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secretory particle degradation, and their fragmentation into negative feedback peptides (e.g. 
catestatin and vasostatin; D’amico, Ghinassi, Izzicupo, Manzoli, & Di Baldassarre, 2014; T. Kim, 
Tao-Cheng, Eiden, & Loh, 2001; Koshimizu, Cawley, Kim, Yergey, & Loh, 2011; Kvetnansky et 
al., 2009). Transcriptional upregulation of chromogranins may be stimulated by protein kinase D 
(PKD), PKA, and extracellular signal-regulated kinase (ERK)-dependent mechanisms 
(Mahapatra, Mahata, O’Connor, & Mahata, 2003; von Wichert et al., 2008). 
When CAs are localized to their vesicles, they are ready for signal-mediated exocytosis. 
Most signals for exocytosis depolarize the cell membrane and potentiate the influx of Ca2+ via 
voltage-gated channels. This Ca2+ influx then structurally modifies vesicle fusion proteins and 
facilitates exocytosis (Rizo & Rosenmund, 2008). In neurons, action potential depolarization is 
sufficient for voltage-gated Ca2+ channels (VGCCs) to open (Jackson, Trout, Brain, & Cunnane, 
2001). In chromaffin cells, VGCC activation occurs when ACh binds to nicotinic receptors 
(nAChRs), resulting in Na+ influx and K+ efflux (Sala, Nistri, & Criado, 2007). Aside from these 
main stimuli for secretion, many receptors function to potentiate CA secretion by increasing 
depolarization, while other receptors function to inhibit CA secretion by hyperpolarization (Lodish 
et al., 2000). Further, the activity of nAChRs can be modulated at allosteric sites by certain 
compounds like substance P and calcitonin gene-related peptide (CGRP; Sala et al., 2007). 
The last primary method to regulate CAs is their rate of breakdown into metabolites. There 
are only three types of enzymes that initiate the metabolism of CAs: monoamine oxidases (MAO-
A and MAO-B), catechol-O-methyltransferases (COMTs), and for DA and NE alone, 
semicarbazide-sensitive amine oxidases (SSAOs; Axelrod, 1959; Boomsma, Bhaggoe, van der 
Houwen, & van den Meiracker, 2003). Through a series of succeeding metabolic reactions, the 
final metabolite of NE and Epi is mostly vanillylmandelic acid (VMA), while the final metabolite 
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of DA is mostly homovanillic acid (HVA; Eisenhofer et al., 2004). An alternative metabolic 
mechanism is the conjugation of CA metabolites with sulfate or glucuronide. Conjugation 
reactions appear to be important for the excretion of metabolites, but not for the overall rate of CA 
metabolism (Boobis, Murray, Jones, Reid, & Davies, 1980). MAOs and COMTs are localized 
intracellularly in most tissues, while SSAOs can be localized to the cell membrane, cytosol, or in 
the circulation (Boomsma et al., 2003; Uhlen et al., 2015). However, most CA metabolism is 
catalyzed by MAOs and COMTs and occurs at the site of synthesis (i.e. pre-synaptic terminals and 
chromaffin cells (Eisenhofer et al., 2004). Pre-synaptic terminals predominantly metabolize CAs 
via MAOs, and chromaffin cells metabolize CAs with both MAOs and COMTs (Kvetnansky et 
al., 2009). In cells expressing the extraneuronal monoamine transporter (EMT) gene, CAs can be 
transported intracellularly to be metabolized in different tissues as well (Kvetnansky et al., 2009). 
MAOs are flavoenzymes and use a flavin adenine dinucleotide (FAD) cofactor to deaminate CAs, 
producing hydrogen peroxide (H2O2) in the process (Edmondson, Binda, Wang, Upadhyay, & 
Mattevi, 2009). COMTs require SAM as a cofactor for their O-methylation of CAs (Tsao, 
Diatchenko, & Dokholyan, 2011). SSAOs require copper and a quinone cofactor and produce 
aldehyde metabolites, H2O2, and ammonia (Boomsma et al., 2003; Holt et al., 1998). The 
transcription of MAOs and COMTs can both be altered by steroid hormones, specificity protein 1 
(SP1) activation, and epigenetic methylation in their promoters (Abdolmaleky et al., 2006; 
Schendzielorz, Rysa, Reenila, Raasmaja, & Mannisto, 2011; Tenhunen, 1996; Zwart, Verhaagh, 
Buitelaar, Popp-Snijders, & Barlow, 2001). Recently, it was demonstrated that hypoxia can induce 
the expression of SSAOs (Y. Zhang et al., 2017). Regulators like SP1 activation and hypoxia also 
stimulate increases in CA activity, making the metabolizing enzymes part of a negative feedback 
mechanism. 
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1.3.2 – Adrenomedullary Cell Signals for Catecholamine Regulation 
Interestingly, chromaffin cells express all major proteins that regulate CA synthesis, 
storage, secretion, and metabolism. This is one reason why the adrenal medulla is the area of focus 
for this current study. 
 There are several key hormones that signal to the adrenal medulla from the extracellular 
environment. This tissue is innervated by a sympathetic splanchnic nerve that releases ACh and 
an assortment of other signaling molecules. Besides ACh, nerve terminals can release pituitary 
adenylate cyclase-activating polypeptide (PACAP), vasoactive intestinal peptide (VIP), 
neuropeptide Y (NPY), enkephalins, substance P, somatostatin, and CGRP (Livett & Marley, 
1993). Additionally, the extracellular environment contains signaling elements that originate from 
chromaffin granule exocytosis. Along with CAs, these granules release substances like adenosine 
triphosphate (ATP), Ca2+, adrenomedullin, chromogranin metabolites, natriuretic peptides, NPY, 
VIP, enkephalins, substance P, and CGRP (Crivellato, Nico, & Ribatti, 2008). Other chemical 
signals are from blood vessels that pass through the adrenal cortex (E. J. Whitworth, Kosti, 
Renshaw, & Hinson, 2003). From the blood, chromaffin cells can be affected by signals like 
cortisol, nerve growth factor (NGF), Ang II, low oxygen (hypoxia), and reactive oxygen species 
(ROS) like peroxides, superoxides, NO, and hydroxyl radicals (Crispo, Ansell, Ubriaco, & Tai, 
2011; K. T. Kim, Park, & Joh, 1993; Lillien & Claude, 1985; H.-J. Lim, Lee, & Lim, 2013). 
Frequently, these factors change the membrane voltage potential, bind allosterically to receptors, 
or alter TF expression via intracellular signaling pathways. Five commonly activated signaling 
pathways involved in CA regulation are the PKC, ERK/MAPK, PKA, glucocorticoid, and hypoxia 
pathways (Figure 3).  
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Figure 3: Common chromaffin cell signals and transcription factor activations. Transcription 
factors are marked in green. Signals used for the treatment of cells in this study are marked as gold 
diamonds. Equal signs show when two signals have an equivalent function. Extracellular signals 
that do not cross the outer membrane are marked as blue rectangles. Membrane receptors are 
highlighted with light purple. Signals that can cross plasma membranes are shown as triangles. 
Circles indicate ion transport. Ubiquitination and hydroxylation are abbreviated as Ub and OH, 
respectively. The central signaling kinases, PKC, PKA, and ERK, are highlighted with light red. 
All other signaling mediators are shown in white. For the full names of these signaling molecules, 
see the List of Abbreviations. 
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G protein-coupled receptors (GPCRs) that interact with Gαq (e.g. angiotensin type-1 receptors – 
AT1Rs, muscarinic acetylcholine receptors – mAChRs, and α1 adrenergic receptors) propagate 
their signal by activating particular phospholipase C subtypes (PLC; Guimarães & Moura, 2001; 
Gwathmey, Alzayadneh, Pendergrass, & Chappell, 2012; Harada, Matsuoka, Miyata, Matsui, & 
Inoue, 2015). PLC cleaves phosphatidylinositol 4,5-bisphosphate (PIP2), producing inositol 1,4,5-
trisphosphate (IP3) and diacylglycerol (DAG; Wu-Zhang & Newton, 2013). IP3 releases Ca
2+ from 
the endoplasmic reticulum via the IP3 receptor, which activates various isoforms of PKC (Wu-
Zhang & Newton, 2013). DAG also interacts with certain isoforms of PKC and another regulatory 
pathway, PKD (Rozengurt, 2011; Wu-Zhang & Newton, 2013). Through the inhibition of Raf 
kinase inhibitory protein (RKIP), PKC indirectly activates the ERK/MAPK pathway via Raf-1 
(Corbit et al., 2003). ERK activation indirectly phosphorylates TFs like cAMP response element-
binding protein (CREB) and directly phosphorylates TFs such as Elk-1 (Zhang & Liu, 2002). Elk-
1 further propagates this signal by increasing mRNA levels for the TFs, early growth response 
protein 1 (EGR-1) and c-Fos (a subunit of activator protein 1 – AP1; Monje, Hernández-Losa, 
Lyons, Castellone, & Gutkind, 2005; Zhang & Liu, 2002). Interestingly, the NGF tyrosine receptor 
kinase, TrkA, can strongly activate both PLC/PKC and ERK directly through protein interactions, 
and indirectly via the protein kinase B/Akt (PKB) pathway (Cosgaya & Shooter, 2008; Powers, 
Shahsavari, Tsokas, & Tischler, 1999). Cell survival or apoptotic pathways can be induced by 
another NGF receptor, p75, but this mechanism is stress-dependent (Cosgaya & Shooter, 2008). 
Other extracellular signals can induce PKA activation or inhibition for the regulation of 
CAs. For example, nAChRs, β-adrenergic receptors, and the PACAP/VIP family of receptors 
(particularly PAC1 and VPAC1) are all activators of PKA (Conconi, Spinazzi, & Nussdorfer, 
2006; Guimarães & Moura, 2001; Marley, Thomson, & Bralow, 1995). In contrast, neuropeptide 
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Y receptors, somatostatin receptors, and P2Y purinergic receptors inhibit PKA (Ben-Shlomo & 
Melmed, 2010; Powell, Teschemacher, & Seward, 2000; Zheng, Zhang, & Hexum, 1997). With 
the exception of nAChRs, all these receptors are GPCRs that interact with Gαs to activate adenylate 
cyclase or Gαi to inhibit adenylate cyclases. G proteins bind to transmembrane adenylate cyclases 
(TM-ACs), while nAChRs most likely activate a soluble form of adenylate cyclase (Sol.-AC; 
Hollenhorst, Lips, Kummer, & Fronius, 2012). When ACs are activated, they produce cAMP from 
ATP, which then activates PKA (Yan, Gao, Cui, Zhang, & Zhou, 2016). This activation is 
proceeded by the phosphorylation and stimulation of TFs like SP1, activator protein 2 (AP2), and 
CREB (Delghandi, Johannessen, & Moens, 2005; Garcı́a, Campillos, Marina, Valdivieso, & 
Vázquez, 1999; Rohlff, Ahmad, Borellini, Lei, & Glazer, 1997). Like the PKC pathway, PKA can 
activate ERK and its related TFs. Instead of Raf1 phosphorylation, cAMP and PKA trigger this 
pathway through a Ras-related protein 1 (Rap1)-Braf mechanism (Emery, Eiden, Mustafa, & 
Eiden, 2013; Takahashi, Li, Dillon, & Stork, 2017). Finally, cAMP has the ability to increase the 
stability of glucocorticoid receptor (GR) mRNA, and SP1 can increase GR transcription (Peñuelas, 
Encío, López-Moratalla, & Santiago, 1998; Suehiro et al., 2004). 
GR is a unique TF that plays a role in glucocorticoid signaling and the regulation of CAs. 
Without the stimulation of glucocorticoids, GR is bound to heat shock proteins (particularly 
HSP90), which inhibits its TF function (Drouin et al., 1992). When glucocorticoids passively cross 
the plasma membrane, they can bind to GR and inhibit HSP binding. This inhibition then leads to 
GR homodimerization and TF activation (Drouin et al., 1992). 
The hypoxia-inducible factor 1α (HIF1α) is another TF that is important for CA regulation. 
In normoxic conditions, von Hippel-Lindau protein (pVHL) can bind to an oxygen-dependent 
domain (ODD) on HIF1α (Pugh & Ratcliffe, 2003). pVHL then ubiquitinates HIF1α and targets it 
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for proteasome degradation (Pugh & Ratcliffe, 2003). This process only occurs if the ODD is 
hydroxylated by the oxygen-dependent specific proteins, prolyl-4-hydroxylase (PHD) and factor 
inhibiting HIF1 (FIH; Marxsen et al., 2004). Under hypoxic conditions, hydroxylation and pVHL 
binding are inhibited and HIF1α is stabilized, allowing for it to dimerize with HIF1β and act as a 
TF (Dengler, Galbraith, & Espinosa, 2014). This HIF1 heterodimer binds to hypoxia response 
elements (HREs), and also increases the expression of other important TFs in CA regulation, 
notably SP1 and EGR-1 (Tai, Wong-Faull, Claycomb, & Wong, 2010). Another effect of HIF1α 
activation is an increase in the level of certain ROS, which damage macromolecules (e.g. proteins, 
lipids, and nucleic acids) and modulate the activity of signaling proteins like tyrosine phosphatases 
(PTPs) and PKB (Crispo et al., 2011; Ray, Huang, & Tsuji, 2012). In many cases of elevated ROS, 
HIF1α hydroxylases are inhibited, further stabilizing the activity of this TF (Qutub & Popel, 2008). 
In other cases, such as those involving NO, these hydroxylases are activated (Hagen, Taylor, Lam, 
& Moncada, 2003). To add, NO can alternatively function to activate MAPKs like ERK1/2 and 
p38 through cyclic guanosine monophosphate (cGMP) and protein kinase G (PKG) mechanisms 
(Browning, McShane, Marty, & Ye, 2000; Francis, Busch, Corbin, & Sibley, 2010). Therefore, 
depending on the activity of ROS-generating mechanisms (e.g. hypoxia, membrane oxidases, NO 
synthases – NOSs, and mitochondrial respiration), HIF1α activity and CA regulation can be altered 
in various ways. 
Most of these TFs are especially important for regulating CA biosynthesis enzymes. The 
TH promoter contains many regulatory elements comprised of a SP1/EGR-1 binding site, AP1 and 
AP2 activating regions (AP1ARs and AP2ARs), a HRE, a CREB response element (CRE), and in 
the case of rats and mice, glucocorticoid response elements (GREs; Kvetnansky et al., 2009; J. 
Lim, Yang, Hong, & Kim, 2000). An enhancer box (E-box), which binds dimers of variable TFs, 
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is another activating site in the promoter of the TH gene (Desbarats, Gaubatz, & Eilers, 1996; 
Kvetnansky et al., 2009). Like the TH promoter, the DBH promoter contains an AP1AR, an 
AP2AR, a CRE, an SP1 response element (SP1RE), an E-box, an EGR-1 binding site (EBS), and 
a GRE (Kobayashi, Kurosawa, Fujita, & Nagatsu, 1989; Kvetnansky et al., 2009; Seo, Yang, Kim, 
& Kim, 1996). While most of these regulatory elements increase the expression of DBH, the EGR-
1 binding to the promoter inhibits DBH expression (Cheng, Serova, Glazkova, & Sabban, 2008). 
As for the PNMT promoter, it contains GREs, EBSs, SP1REs, AP2ARs, and a low-affinity HRE 
(Kvetnansky et al., 2009; Tai, Wong-Faull, Claycomb, & Wong, 2009). The characteristics of 
these promoters indicate that PKA, PKC, ERK, glucocorticoid, and hypoxia signaling are all 
important for the regulation of these biosynthesis enzymes. Therefore, stimulating or inhibiting 
these signaling mechanisms at the cellular level is an effective way to determine new regulators of 
CA biosynthesis.  
1.3.3 – The PC12 Cell Model of Catecholamine Synthesis 
 Many studies involving the regulation of CA biosynthesis use the PC12 cell model. These 
cells are derived from undifferentiated rat pheochromocytoma cells (Greene & Tischler, 1976). 
Pheochromocytoma cells express the biosynthesis enzymes at an elevated level (with the exception 
of PNMT, which is unchanged) and have a depressed level of MOAs and COMTs (Jarrott & Louis, 
1977). Pheochromocytoma cells also have a notable decrease in the level of succinate-coenzyme 
Q reductase (SQR), the second complex of the electron transport chain and an enzyme of the citric 
acid cycle (Jarrott & Louis, 1977). PC12 cells do not express the E-box-binding TF, myc-
associated factor X (Max), possibly altering CA regulatory pathways (Hopewell & Ziff, 1995). 
While chromaffin cell are specialized to contain mostly NE or Epi in their vesicles, the majority 
of CAs in PC12 cell vesicles is DA (Westerink & Ewing, 2008). A signaling process of PC12 cells 
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to produce Epi or NE can be carried out by treating them with NGF, PACAP, or the synthetic 
glucocorticoid, dexamethasone (Dex; Beaujean et al., 2003; Das, Freudenrich, & Mundy, 2004; 
Vaudry et al., 2002). When signaled by NGF, PC12 cells differentiate by proliferation and the 
formation of neurite extensions (Greene & Tischler, 1976). NOS induction is another important 
change that occurs during NGF differentiation (Schonhoff, Bulseco, Brancho, Parada, & Ross, 
2001; Sheehy, Phung, Riemer, & Black, 1997). PACAP-induced differentiation can occur as well, 
which increases neurite outgrowth but inhibits proliferation (Vaudry et al., 2002). Stimulation of 
PC12 cells by Dex increases the production of Epi and can attenuate the NGF-provoked neurite 
outgrowth, while increasing proliferation (K. T. Kim et al., 1993; Terada et al., 2014). PC12 cells 
are valuable for in vitro studies because there are many cell treatments that are used to replicate 
increases in CA biosynthesis in chromaffin cells. For example, cobalt chloride (CoCl2) binds 
HIF1α’s ODD and inhibits pVHL ubiquitination, resulting in hypoxic-like conditions (Crispo et 
al., 2011; Yuan, Hilliard, Ferguson, & Millhorn, 2003). Treatment of PC12 cells with forskolin 
(Fsk) activates AC and PKA/ERK regulatory mechanisms (Seamon & Daly, 1981). Moreover, the 
use of phorbol 12-myristate 13-acetate (PMA) on PC12 cells reproduces DAG’s activation of 
specific subtypes of PKC (i.e. Ca2+-independent subtypes; Wu-Zhang & Newton, 2013). Using 
PC12 cells, with control of these intracellular pathways, allows for the detection of new genes that 
are involved with CA biosynthesis. If a gene is regulated in a similar manner to the biosynthesis 
enzymes, it is possible that this gene is involved with CA regulation. In the present study, this cell 
model will be used to determine if the novel protein, renalase, is related to CA biosynthesis in 
chromaffin cells. 
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1.4 – The Physiological Importance of Renalase 
1.4.1 – A Novel Player in Catecholamine Regulation 
 Renalase was first discovered in 2005 and was proposed to catalyze the oxidation of 
circulating CAs (Xu et al., 2005). In this same study, renalase was shown to oxidize DA, NE, and 
Epi in the presence of FAD. This oxidation was detected by measuring H2O2 and fluorescence 
using a MAO assay kit. Unlike MAOs or COMTs, renalase converts CAs to aminochrome 
products (Desir, Tang, et al., 2012). Its highest affinity was towards DA and its lowest affinity was 
towards NE (Xu et al., 2005). Later studies confirmed these oxidation reactions using high-
performance liquid chromatography (HPLC)-based methodologies, but claimed that renalase’s 
highest affinity was towards Epi, and its weakest affinity was towards DA (Quelhas-Santos et al., 
2015). Xu et al. also administered recombinant renalase to rats and observed negative inotropic 
and chronotropic effects, as well as a reduction in BP within 30s of injection (2005). Two renalase 
knockout (KO) models in mice have been generated, demonstrating increased BP, HR, and 
circulating CA levels, and decreased body mass (Quelhas-Santos et al., 2014; Y. Wu et al., 2011). 
If these studies are correct, and renalase’s function in vivo is to degrade CAs, renalase would be 
one of the most important proteins for the discovery of new medical treatments for hypertension, 
and pathophysiological mechanisms of this disease.  
1.4.2 – Potential Roles in Disease 
 Shortly after the discovery of renalase, a study of 2586 individuals from a northern Chinese 
Han population found eight SNPs in the human renalase gene (Zhao et al., 2007). In the same 
study, two of these SNPs were associated with hypertension: an rs2576178 GG genotype in the 5’ 
flanking region, and an rs2296545 CC genotype coding for a Glu37Asp substitution in exon 2. 
Further, a meta-analysis study has confirmed the association of the rs2296545 SNP and 
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hypertension, but not for the rs2576178 SNP (Lv et al., 2016). Because there is a common 
comorbidity of hypertension and diabetes, 892 diabetes patients of Polish origin with or without 
hypertension were genotyped for three renalase SNPs (Buraczynska, Zukowski, Buraczynska, 
Mozul, & Ksiazek, 2011). The rs2296545 SNP was significantly more prevalent in hypertensive 
diabetic patients compared to normotensive patients and healthy controls (Buraczynska et al., 
2011). Interestingly, Buraczynska et al. also found that the rs2576178 SNP was significantly more 
prevalent in all diabetes patients compared to healthy controls (2011). More recently, the two 
major renalase SNPs have also been associated with ischemic stroke and coronary heart disease in 
a northern Chinese Han population (X. Li et al., 2014; R. Zhang et al., 2013). Other studies 
including populations from Sweden, Bosnia & Herzegovina, and China did not show an 
association between hypertension and these SNPs (Fava et al., 2012; Kiseljakovic et al., 2016; Shi 
& Wang, 2015). Overall, renalase SNPs can be associated with hypertension and several diseases, 
but this finding appears to be population-dependent.  
 Altered renalase activity has been shown in a genetic animal model of hypertension, the 
spontaneously hypertensive rat (SHR). SHR plasma compared to normotensive rats (Wistar-Kyoto 
rats – WKYs) had a reduced level of renalase (Jiang et al., 2012). In the kidney of SHRs, authors 
found increased renalase mRNA in rats with severe hypertension, but not with moderate 
hypertension (Fedchenko, Globa, Buneeva, & Medvedev, 2013). Yet, another study observed a 
decrease in renalase protein in kidneys of SHRs (Jiang et al., 2012). In the heart and brain, SHRs 
had increased and decreased renalase mRNA, respectively (Fedchenko et al., 2013). These studies 
demonstrate that renalase regulation is genetically regulated, but also by context and tissue-
dependent variables that are yet to be discovered.  
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 The activity of renalase is also altered in many pathological states. In circulation, renalase 
levels have been shown to negatively correlate with systolic BP in patients with resistant 
hypertension (Schlaich et al., 2010). Shortly after its discovery, renalase plasma levels in end-stage 
renal disease (ESRD) patients was found to be significantly lower (Xu et al., 2005). In kidney and 
heart transplant recipients, renalase plasma levels were increased (Przybylowski, Koc-Zorawska, 
Malyszko, Mysliwiec, & Malyszko, 2010; Zbroch, Małyszko, Małyszko, Koc-Żórawska, & 
Myśliwiec, 2012). Lower GFR in kidney transplant individuals is associated with increased 
markers for NO metabolism, which may be an effect from the increased plasma renalase levels 
that were also observed (Stojanovic et al., 2015). Generally, renalase plasma levels are increased 
in hemodialysis and peritoneal dialysis patients (Malyszko et al., 2015; Zbroch, Koc-Zorawska, 
Malyszko, Malyszko, & Mysliwiec, 2013; Zbroch, Malyszko, Malyszko, Koc-Zorawska, & 
Mysliwiec, 2012). In subtotal nephrectomized rats (5/6Nx) and several forms of acute kidney 
injury (AKI), renalase plasma levels are decreased, making renalase a potential biomarker for 
kidney function (Desir & Peixoto, 2014; H. T. Lee et al., 2013; Wybraniec & Mizia-Stec, 2015). 
Another renal pathology that may involve renalase is the production of simple renal cysts (SRCs); 
patients with SRCs were found to have lower circulating renalase levels (Elcioglu et al., 2015). 
Alternative to kidney disorders, renalase has been implicated in other pathologies across the body 
like atherosclerosis, cancer (specifically melanoma and pancreatic cancer), lupus nephritis, and 
preeclampsia (Guo et al., 2016; Hollander et al., 2016; Qi et al., 2015; Yılmaz, Akkaş, Yıldırım, 
Yılmaz, & Erdem, 2016; Zhou et al., 2015). Because of renalase’s involvement with these 
pathologies, administration of recombinant renalase for medical purposes is a frequently 
researched topic. Renalase has the ability to lower BP and provides protective effects for ischemic 
or cisplatin-induced AKI, cardiac ischemia, proteinuria, glomerular hypertrophy, and interstitial 
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fibrosis (Desir & Peixoto, 2014; Du et al., 2015; H. T. Lee et al., 2013; L. Wang et al., 2014; Y. 
Wu et al., 2011; Yin et al., 2016).  
1.4.3 – Localization of Renalase 
 As a secretory protein, renalase can be isolated from plasma and urine (Xu et al., 2005). 
Urinary renalase appears to be consistently active and plasma renalase is only activated by certain 
signals like Epi (G. Li et al., 2008). Therefore, the activity of renalase may be highly variable and 
dependent on its localization.  
The name, renalase, stems from the idea that the kidney provides a large fraction of the 
circulating protein. In the kidney, renalase is mostly expressed in podocytes, mesangial cells, and 
tubule cells (F. Wang et al., 2012). In this same study, Wang et al. detected renalase protein in the 
supernatant of tubule cells, but not from the supernatants of mesangial cells or podocytes (2012). 
Protein localization in the glomerular cells appears to be more punctiform than the tubule cells, 
suggesting that renalase is localized to intracellular vesicles. If renalase is indeed localized to 
vesicles, it may be secreted by glomerular cells in a more transient and signal-dependent manner.  
It is now evident that there are alternative sources of circulating renalase throughout the 
body. Renalase is expressed in the heart, vasculature, liver, pancreas, lung, thyroid, adipocytes, 
immune cells, small intestine, skeletal muscle, brain, peripheral nerves, reproductive tissues, 
mouse embryo (12.5 days), and adrenal glands. (Guo et al., 2016; Hennebry et al., 2010; Hollander 
et al., 2016; Ramanjaneya et al., 2014; J. Wang et al., 2008; Xu et al., 2005; Zhou et al., 2013). In 
the adrenal glands, it is strongly expressed in the cortex and moderately expressed in the medulla 
(Zhou et al., 2013). Despite these findings, renalase expression has yet to be analyzed in various 
other tissues and cell types. For example, its expression has not been observed in undifferentiated 
cell types like the PC12 cell model. 
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1.4.4 – Structure and Isoforms of Renalase 
 Initial studies on renalase’s structure identified that it contained an N-terminal signal 
sequence, a Rossmann-fold FAD-binding site, and a monoamine oxidase domain (Figure 4; Xu et 
al., 2005). In 2011, these structures were verified by Milani et al., who first observed the crystal 
structure of renalase. These features are highly conserved between species, with its signal sequence 
being identified in a range of animals like rats, zebrafish, and even sea urchins (J. Wang et al., 
2008). Although renalase’s structure appears to resemble MAOs, their sequences of amino acids 
are only 13.2% similar (Xu et al., 2005). Because of renalase’s differential activity in plasma and 
urine, it has been hypothesized that its protein also exists as prorenalase (G. Li et al., 2008). It has 
been thought that the activation of prorenalase possibly involves dimerization, which is observed 
when renalase is collected from urine (Xu et al., 2005). However, mass spectrometry later 
identified there to be only a single monomeric form in urine (Fedchenko et al., 2012). Therefore, 
the structural changes and/or modifications that activate prorenalase have yet to be identified. The 
presence of an overlapping signal sequence with the FAD-binding site indicates that the active site 
of the enzyme may be partially cleaved after secretion. It is possible that renalase secretion 
involves an alternative pathway that evades cleavage, but recent studies discovered that urinary 
renalase lacks its signal sequence (Desir, Wang, & Peixoto, 2012; Fedchenko et al., 2015). If 
extracellular renalase lacks this functional domain, its mechanism of action in the circulation must 
be reconsidered. 
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Figure 4: Domain layout of renalase. Renalase contains an N-terminal signal sequence, FAD-
binding site, and monoamine oxidase domain. Image is modified from Hennebry et al., 2010. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Transcript variants of renalase. The ten exons of the renalase gene are numbered in blue, 
red or green. All transcript variants include exon 6. Image is modified from L. Wang et al., 2014. 
In that study, three active peptides were synthesized from exon 6 and one scrambled peptide. 
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In humans, seven transcript variants for renalase have been identified thus far (Figure 5). 
Of these seven variants, only two protein products have been identified in humans. These two 
proteins are named hRenalase1 and hRenalase2 (Fedchenko, Kaloshin, Mezhevikina, Buneeva, & 
Medvedev, 2013). hRenalase1 is 342 amino acids long and has a molecular weight of 37.85kDa 
(Xu et al., 2005). hRenalase2, on the other hand, contains 315 amino acids and has a molecular 
weight of 34.95kDa (Fedchenko et al., 2013). While the function of each transcript variant is 
currently unknown, there are some important similarities between them. For instance, all but one 
variant (variant 7) contain the signal sequence (Hennebry et al., 2010; L. Wang et al., 2014). 
Another similarity is the inclusion of exon 6 in all variants (L. Wang et al., 2014). The three-
dimensional confirmation of renalase allows for a particular set of amino acids, coded by exon 6, 
to be solvent exposed (Milani et al., 2011; L. Wang et al., 2014). Hence, this area is now under 
investigation to determine if renalase can function as a hormone. 
1.4.5 – Recent Insights into Mechanisms of Activity 
 Such structural details have led to the discovery of several signaling peptides derived from 
renalase’s 6th exon (Figure 5; L. Wang et al., 2014). Further studies of the renalase peptide 220 
(RP-220) have revealed that it can bind to PMCA4b on proximal tubule cells (L. Wang, Velazquez, 
Chang, Safirstein, & Desir, 2015). When recombinant renalase or RP-220 bind to this receptor, 
they stimulate small changes in the phosphorylation status of ERK1/2 but larger changes in the 
status of p38 phosphorylation (L. Wang et al., 2015). When a lysine-lysine-arginine (KKR) 
sequence in RP-220 is replaced with alanine, the protective effects of renalase signaling are 
inhibited (L. Wang et al., 2015). Nevertheless, this signaling mechanism does not complete our 
understanding of renalase’s regulation of BP and CAs. For this, further analysis should be 
performed on PMCA4b receptor structural changes upon substrate binding. One possible 
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mechanism that would allow for this receptor to regulate BP and CAs is a downstream activation 
of NOS. Such an activation is possible because PMCA4b commonly binds and interacts with 
neuronal NOS (nNOS; Schuh, Uldrijan, Telkamp, Röthlein, & Neyses, 2001). Moreover, 
activation of PMCA4b by renalase could potentiate a further reduction in intracellular Ca2+, 
resulting in membrane hyperpolarization in tissues like the adrenal medulla. PMCA subtype 
expression is highly tissue-dependent and therefore, more research should be done to determine if 
renalase similarly signals PMCAs in other cell types (Brandt, Neve, Kammesheidt, Rhoads, & 
Vanaman, 1992). 
 In 2015, Beaupre et al. discovered another alternative function of renalase. Using its FAD-
binding domain, renalase was found to be capable of oxidizing isomeric forms of reduced 
nicotinamide adenine dinucleotide with or without phosphate (NAD(P)H; Beaupre, Hoag, Roman, 
Försterling, & Moran, 2015). These isomers were 6-dihydroNAD(P) and 2-dihydroNAD(P) 
(6DHNAD(P) and 2DHNAD(P)). In an enzymatic reaction that consumes oxygen and produces 
H2O2, these isomers are converted to β-NAD(P)+ (Figure 6; Beaupre, Hoag, Roman, et al., 2015).  
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Figure 6: Enzymatic reaction mechanism of renalase. It is proposed that renalase oxidizes isomers 
of reduced nicotinamide adenine dinucleotide (NAD(P)H), producing hydrogen peroxide (H2O2) 
in the process. Image is taken from Beaupre, Hoag, Roman, et al., 2015. 
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If the FAD-binding site is cleaved during secretion, this reaction most likely takes place 
intracellularly. The isomers that were shown to react with renalase could be physiologically 
relevant because of their ability to inhibit the NAD(P)H-dependent enzymes malate and lactate 
dehydrogenase (Beaupre, Hoag, Roman, et al., 2015). It is important to note that other ROS, in 
addition to H2O2, might be produced by renalase. Elevated ROS would occur if ROS-producing 
NADPH oxidases (NOXs) are also inhibited by the NAD(P)H isomers (Panday, Sahoo, Osorio, & 
Batra, 2015). NOSs are dependent on NADPH too, and this could make renalase an activator of 
NO via this enzymatic mechanism (Förstermann & Sessa, 2012). Unfortunately, there is only a 
limited amount of information on the relationship between ROS and renalase. This area should be 
further investigated for a better understanding of the physiological implications of renalase. 
1.4.6 – The Regulation of Renalase 
 Revealing regulatory mechanisms of renalase is a crucial step towards understanding its 
function. Circulating CAs (Epi, NE, and DA) all regulate the synthesis, secretion, and activity of 
renalase (G. Li et al., 2008). Activity and secretion were quickly upregulated (within 15min), and 
synthesis was only upregulated after 12 hours (G. Li et al., 2008). In this case, activity was 
measured by CA metabolism, and not hormonal function or NADPH oxidation. If the prorenalase 
theory is true, CAs would be partly responsible for the activation of enzymatic renalase. Increased 
renalase expression by CAs has also been verified by other studies, where SP1 and nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-κB) were the mediators of increased 
expression (Sonawane et al., 2014; F. Wang et al., 2014). Additionally, renalase may be regulated 
by the D5 receptor in proximal tubule cells through an alternative signaling mechanism that 
involves PKC instead of PKA (S. Wang et al., 2014). An issue with this finding is that it only 
applied to the dimerized form of renalase, which was previously identified as albumin, and not 
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renalase (Fedchenko et al., 2012). The minimal treatment time for these D5-based regulations was 
12 hours. As previously stated, renalase expression is also dependent on kidney function. In 
addition to renalase’s relationship with factors like AKI and GFR, salt intake may be a regulator 
of renalase expression (Desir & Peixoto, 2014; Stojanovic et al., 2015). Evidence for this claim 
was found when rats were fed a high-salt diet and renalase expression in the kidney and plasma 
was decreased (Y. Wang et al., 2015). This decrease was not altered by the use of an ARB or an 
ACE inhibitor (Y. Wang et al., 2015). In white muscle fibers, it was found that renalase protein 
and mRNA is decreased in untrained rats subjected to endurance training exercises, possibly as a 
function to redistribute blood flow (Czarkowska-Paczek, Zendzian-Piotrowska, Gala, Sobol, & 
Paczek, 2013). The influence of fat metabolism on renalase expression is beginning to be examined 
as well. In apolipoprotein E (ApoE) knockout mice, renalase expression is robustly increased in 
fat tissue (Zhou et al., 2015). So far, research on miRNA regulation of renalase has found the 
involvement of miR-29 and miR-146 in the post-transcriptional downregulation of renalase 
(Dziedzic et al., 2017; Kalyani et al., 2015). These miRNA could play a role in other regulators of 
CAs like COMT, NET, and D1Rs (Kalyani et al., 2015). The influence of gonadotropin-releasing 
hormone (GnRH) on renalase expression is also a new finding; GnRH antagonism decreased 
renalase expression in reproductive tissues (Zhou et al., 2013). Therefore, the transient activity of 
GnRH might help explain our finding that renalase mRNA is lower in female kidneys (Appendix 
A; Tsutsumi & Webster, 2009). Reproductive tissues also demonstrate higher expression of 
renalase in leptin-deficient mice (Zhou et al., 2013). Uninvestigated areas that should be analyzed 
for renalase regulation include apoptotic/stress, differentiation, and cellular remodeling 
mechanisms. 
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A greater understanding of renalase regulation requires the analysis of the renalase 
promoter. Currently, there are only four regulatory elements that have been identified in the 
renalase promoter (Figure 7). So far, there have been no inhibitory binding sites located on the 
renalase promoter. Three of these elements, which bind signal transducer and activator of 
transcription 3 (STAT3), SP1, and zinc-finger binding protein-89 (ZBP-89), were verified by 
Sonawane et al. in 2014. In this same study, other putative binding sites were found, but not 
investigated. Du et al. also identified four HREs in the renalase promoter, one of which being 
verified as a strong activator of transcription (2015). This finding is consistent with the notion that 
hypoxia has been shown to increase renalase expression in the renal cortex for up to 48 hours (F. 
Wang et al., 2015). STAT3’s function is usually to mediate cell survival and inflammatory signals, 
but it has been demonstrated that nicotine (Nic) can also induce STAT3 activation in several cell 
lines (Chen, Ho, Guo, & Wang, 2008; Sonawane et al., 2014). Similar to STAT3, ZBP-89 has a 
role in inflammatory signaling (Borghaei, 2009). However, the physiological implications of its 
regulation of renalase remain to be elucidated. So far, only one study has revealed epigenetic 
regulation of the renalase promoter. In that study, the promoter was found to be inhibited by CpG 
island methylation in Epstein-Barr virus-infected keratinocytes (Birdwell et al., 2014). Ultimately, 
these regulatory mechanisms provide additional evidence that renalase has a homeostatic function 
in the body. 
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Figure 7: Established regulatory elements in the renalase promoter. The scale indicates the number 
of nucleotides upstream from the transcriptional start site (TSS). The exact locations of the binding 
sites are also noted below the transcription factors (TFs). TFs that bind to renalase’s promoter 
include hypoxia-inducible factor 1α (HIF1α), signal transducer and activator of transcription 3 
(STAT3), specificity protein 1 (SP1), and zinc-finger binding protein-89 (ZBP-89).  
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1.4.7 – Current Issues Regarding the Function of Renalase  
 The alternative name for renalase, monoamine oxidase C (MAO-C), is likely to be a 
misnomer. As previously mentioned, only 13.2% of renalase’s amino acid sequence is shared with 
MAO-A (Xu et al., 2005). This partially explains why inhibitors of MAOs (e.g. clorgyline and 
pargyline) do not decrease the activity of renalase (Xu et al., 2005). Since renalase’s discovery, 
there have been speculations about its ability to degrade CAs. Boomsma and Tipton were first to 
criticize renalase’s CA oxidation assay from from Xu et al. in 2005 (Boomsma & Tipton, 2007). 
In their paper, they mention that the production of H2O2 was too slow and corresponded to only 
0.25% of the CA substrates. Antioxidants were not added to these reactions and it has been 
proposed that the production of H2O2 originated from autoxidation of CAs (Boomsma & Tipton, 
2007). HPLC-based techniques have added evidence that renalase does not contribute to the 
breakdown of CAs (Beaupre, Hoag, & Moran, 2015). Renalase’s production of adrenochrome 
incites other questions about its catalytic function. A small number of studies suggest that 
adrenochrome is not a CA metabolite in normal physiology (Axelrod, 1959). Lastly, the secretion 
mechanism of renalase should be analyzed to confirm cleavage of the FAD-binding site within its 
signal sequence. If cleavage does occur in all tissues, renalase could metabolize CAs intracellularly 
in cell types like podocytes and mesangial cells, where the secretion of renalase is likely reduced 
or prevented. 
 If renalase does not oxidize CAs, there is still much to be known about its mechanism of 
action. Intracellularly, the inactivation of NAD(P)H isomers is a possible function (Beaupre, Hoag, 
Roman, et al., 2015). The inhibitory quality of 6DHNAD(P) and 2DHNAD(P) could apply to 
hundreds of enzymes and hence, more research is needed in this area. Renalase’s highly conserved 
signal sequence indicates it is an important signaling molecule too. Once secreted, renalase could 
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act as a hormone by binding to PMCA4b (L. Wang et al., 2015). With only proximal tubules being 
analyzed so far, this signaling ability should be investigated in other tissues and with other types 
of PMCAs. Nevertheless, there is no complete connection between this signaling mechanism and 
the elevated CAs found in the renalase KO mice. Although p38 and ERK phosphorylation are 
consequences of renalase signaling, it is unknown if PMCA4b binding also increases Ca2+ efflux 
and nNOS activation. Together, these intracellular signaling pathways could alter CA biosynthesis, 
storage, secretion, and breakdown. The role of renalase in the adrenal glands should be investigated 
because they express renalase at a level that is among the highest in the body (Zhou et al., 2013). 
In this tissue, the cortex, medulla, and the splanchnic nerve could secrete renalase and create high 
extracellular concentrations of renalase in the adrenal medulla. Yet, it is still only a question 
whether autocrine, paracrine, and endocrine signals of renalase affect the largest producer of 
circulating CAs in the body. 
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1.5 – Hypothesis & Objectives 
The purpose of this study is to examine the potential role of renalase in the regulation of 
CA biosynthesis in the adrenal medulla. It is hypothesized that renalase is part of a negative 
feedback mechanism in the adrenal medulla that functions to reduce CA biosynthesis, thereby 
regulating circulating CAs and consequently, BP. In this study, there are 3 objectives to test this 
hypothesis: 
Objective 1: Examine the regulation of renalase by signal activators of CA biosynthesis. This 
objective was performed using PC12 cells and renalase mRNA and protein levels were both 
analyzed. Signaling molecules in this study were either activators of CA-biosynthesis or Epi itself 
(highlighted in Figure 3). As part of a negative feedback mechanism, it was predicted that renalase 
expression will increase after such treatments.   
Objective 2: Determine if renalase, or its peptide, RP-220, regulates CA-biosynthesizing enzymes. 
mRNA levels in PC12 cells were used to detect changes in CA biosynthesis. Because renalase can 
act as a hormone with PMCA4b, it is possible that a similar or alternative membrane protein can 
induce intracellular signals that regulate CA biosynthesis (e.g. MAPK or NO signaling 
mechanisms; Figure 3). Following renalase treatment, it was predicted that CA-biosynthesizing 
enzyme mRNA levels will decrease.  
Objective 3: Examine the expression of renalase in hypertensive rats. Renalase mRNA and protein 
levels were both compared in the adrenal gland between adult normotensive WKYs and 
hypertensive SHRs. Because of the anti-hypertensive effects of renalase, it was predicted that 
SHRs will have a lower expression of renalase. 
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2 – Materials and Methods 
2.1 – Animal Handling and Tissue Collection 
Male SHRs and WKYs (n = 4) were purchased from Charles River (Wilmington, MA).  
All protocols regarding the handling of animals have been previously described (Nguyen et al., 
2009). Animals were cared for in accordance with the Canadian Council on Animal Care 
guidelines, and were approved by the Laurentian University Animal Care Committee. Adrenals 
were collected at 12 weeks of age and stored at -80oC until use.  
2.2 – Cell Culture 
2.2.1 – Cell Splitting and Counting 
All experiments were performed using rat PC12 cells (Dr. Daniel O’Connor, University of 
California, San Diego, CA). Cells were cultured in Nunclon Delta-treated dishes (ThermoFisher, 
Waltham, MA) using Dulbecco’s Modified Eagle’s Medium (DMEM; Hyclone, Logan, UT) 
containing 5% bovine calf serum (Hyclone), 5% equine serum (Hyclone), and 0.05µg/mL of 
gentamycin sulfate (Sigma-Aldrich, St. Louis, MO). Growth of cells took place in a humidified 
incubator (Forma Scientific model 3130; ThermoFisher) at 37oC supplied with 5% CO2. Cell 
growth and division was monitored and cells were split at a confluency of 80-90%. Before 
splitting, reagents were warmed to 37oC and the cell culture hood was exposed to ultraviolet (UV) 
light for 20min. First, cells were washed twice with autoclaved phosphate-buffered saline (PBS; 
pH = 7.4; 137 mM sodium chloride (NaCl), 2.7 mM potassium chloride (KCl), 8 mM sodium 
hydrogen phosphate (Na2HPO4), and 2 mM monopotassium phosphate (KH2PO4). All reagents for 
PBS were purchased from Sigma-Aldrich, except for NaCl, which was from Thermo-Fisher. 
Washing was followed by a 5min incubation with trypsin-ethylenediaminetetraacetic acid (EDTA; 
1mL per 100mm dish; Gibco, Waltham, MA). Cells were neutralized by adding DMEM (10mL 
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per 100mm dish) and clumps were disturbed by pipetting the cell mixture. Cell viability was 
performed using a Vi-CELL cell counter (Beckman Coulter, Mississauga, ON) as per the 
manufacturer’s instructions.  
2.2.2 – Cell Treatments 
Before cell treatment, cell viability was confirmed to be greater than 90%. 2.75 million 
viable cells (or lower depending on treatment duration) were placed in 35mm dishes (Corning, 
Tewksbury, MA) with DMEM containing charcoal-treated serum (CTM). Cells were grown in 
CTM for 16-24 hours before drug treatment. Treatment concentrations and durations were used 
because of their signaling effects established in previous studies (Table 1). Prior to treatment, all 
signaling substances were diluted to a working concentration in CTM. For the recombinant 
renalase treatments, urea and glycerol (each at 0.1%; ThermoFisher) were used to control for trace 
amounts in the renalase solvent. For the RP-220 treatments, acetonitrile (0.05%; Sigma-Aldrich) 
was used to control for trace amounts in the peptide solvent. PMA, CoCl2, Nic, PACAP, and Ang 
II were purchased from Sigma-Aldrich. Dex, Fsk, H2O2, and Epi were acquired from Cayman 
Chemicals (Ann Arbor, MI), LC Laboratories (Woburn, MA), ThermoFisher, and Alfa Aesar 
(Haverhill, MA), respectively. NGF was provided by Dr. G. Ross (Medical Sciences Division, 
Northern Ontario School of Medicine, Sudbury, ON). Recombinant renalase and RP-220 were 
purchased from Abcam (ab134535 and ab45730, respectively; Cambridge, UK). Treatments for 
mRNA quantitation were completed by aspirating media, washing cells once in warm 1x PBS, and 
adding 500µL of TRI Reagent (Sigma-Aldrich) per 35mm dish. Plates were then stored at -80oC 
until RNA extraction. Cells used for protein quantification were immediately extracted after 
treatment. 
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Table 1: Conditions used for the treatment of PC12 cells.  
Signaling Molecule Treatment 
Concentration(s) 
Treatment 
Duration(s) 
Reference with Similar 
Treatment Conditions 
Phorbol 12-myristate 13- 
acetate (PMA) 
8, 40, 80, 400, & 
800nM for 6h 
1, 6, 12, & 24h 
at 80nM 
Tai & Wong, 2003 
Dexamethasone (Dex) 
0.01, 0.1, 1, 10, & 
100µM for 6h 
1, 6, 12 & 24h 
at 1µM 
Wong, Siddall, Ebert, 
Bell, & Her, 1998 
Cobalt chloride (CoCl2) 
200 & 500µM for 
6h 
1, 6, 12, & 24h 
at 200µM 
Tai et al., 2009; Crispo et 
al., 2011 
Forskolin (Fsk) 10µM 1, 6, 12, & 24h Tai & Wong, 2003 
Epinephrine (Epi) 200µM 24h Sonawane et al., 2014 
Nicotine (Nic) 500µM 24h Sonawane et al., 2014 
Pituitary adenylate 
cyclase-activating 
polypeptide (PACAP) 
10 & 100nM 45m & 6h 
Tai, Wong-Faull, 
Claycomb, Aborn, & 
Wong, 2010; Taupenot, 
Mahata, Mahata, & 
O’Connor, 1999 
Hydrogen peroxide 
(H2O2) 
500µM 30m  
Ito, Nakashima, & 
Nozawa, 1997 
Angiotensin II (Ang II) 100nM 6h 
Yu, Lu, Rowland, & 
Raizada, 1996 
Nerve growth factor 
(NGF) 
500pM 1, 6, 12, & 24h 
Tai, Wong-Faull, 
Claycomb, & Wong, 
2006 
Renalase (Rnls) 50 & 250nM 24h L. Wang et al., 2014 
Renalase peptide 220 
(RP-220) 
1.5 & 8.5µM 24h L. Wang et al., 2015 
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2.3 – RNA Extraction, cDNA Synthesis, and RT-PCR 
2.3.1 – RNA Extraction 
For tissue analysis, whole adrenals were placed in 1mL of TRI Reagent and homogenized 
with a Qiagen TissueLyser (Newtown, PA). Extraction from adrenals was performed using 
Qiagen’s AllPrep DNA/RNA/Protein Mini Kit as per the manufacturer’s instructions. For RNA 
extraction from cells, plates from -80oC were thawed and samples were transferred to tubes. Then, 
100µL of chloroform (per 500µL of TRI Reagent; Sigma-Aldrich) was added, vortexed for 10s, 
and incubated at room temperature for 10min. Samples were then placed in an Eppendorf 5415 R 
centrifuge (Hamburg, Germany) for 20min at 4oC with a speed of 12 000 x g. After centrifugation, 
the top aqueous layer was carefully removed and added to 125µL of isopropanol (per 500µL of 
TRI Reagent; Sigma-Aldrich). This mixture was incubated for 8min at room temperature and 
centrifuged for another 8min at 12 000 x g and at 4oC. The supernatant was removed and the pellet 
was washed in 500µL of 70% ethanol (Commercial Alcohols, Toronto, ON) per 500µL of TRI 
Reagent. A last centrifugation was performed for 5min at 7500 x g and 4oC. Pellets were air-dried 
for no longer than 10min and resuspended in 20-40µL of diethyl pyrocarbonate water (DEPC 
water; reagent and protocol from Fluka/Honeywell, Morris Plains, NJ). Pellets were dissolved in 
DEPC water using an Eppendorf thermomixer R for 10min at 37oC at 1000rpm. Samples were 
stored at -20oC for short-term storage and -80oC for long-term storage. 
2.3.2 – Spectrophotometry and RNA Integrity Analysis 
RNA yield, quality, and purity were quantified using a NanoDrop ND-1000 
spectrophotometer (Wilmington, DE). All samples were confirmed to have a 260/280 ratio 
between 1.90 and 2.05. Visual analysis of RNA integrity was carried out with the electrophoresis 
on a 1% gel containing 0.5µg/mL of ethidium bromide (EtBr; Sigma-Aldrich) and agarose 
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(FroggaBio, Toronto, ON) dissolved in a TBE (Tris-borate-EDTA) buffer. TBE buffer was made 
using MilliQ water (EMD/MilliPore, Billerica, MA) containing 90mM Tris base, 90mM boric 
acid, and 2mM EDTA. These reagents for TBE buffer were purchased through ThermoFisher. 
500ng of each RNA sample was added to 2µL of 6x gel-loading dye and a difference of DEPC 
water to provide a total load volume of 12µL. A water control was prepared using 10µL of DEPC 
water and 2µL of loading dye (30% glycerol and 0.25% bromophenol blue (Sigma-Aldrich)). 5µL 
of 100 base pair (bp) DNA ladder (FroggaBio) was also loaded. Electrophoresis was completed 
using a horizontal electrophoresis apparatus and PowerPac power supply from BioRad (Hercules, 
CA). After electrophoresis for 1 hour at 100V, RNA integrity gels were visualized using a Bio-
Rad UV ChemiDoc analyzer and the Quantity One Software. Samples were considered to have 
acceptable integrity if the 28s band was approximately twice the density of the 18s band. No other 
major bands were visualized during RNA integrity analysis. 
2.3.3 – DNase Treatment and cDNA Synthesis 
 2µL of 10x DNase reaction buffer and amplification grade DNase I (Sigma-Aldrich) were 
added to 2µg of RNA for each sample. A reaction volume of 20µL was achieved by adding extra 
volume of DEPC water. One sample was duplicated for a negative reverse-transcriptase (RT) 
control. Samples were sealed and incubated at room temperature for 15min. 2µL of a stop solution 
(Sigma-Aldrich) was added to each sample, followed by enzyme denaturation for 10min at 70oC. 
The RT reaction protocol was initiated by adding 0.5µg of random primers (Roche, Basel, 
Switzerland) to 1µg of RNA and heating samples for 5min at 70oC. Each sample was mixed with 
2.5µL of a 10mM deoxynucleotide triphosphate (dNTP; Promega, Madison, WI) solution, 10µL 
of 5x reaction buffer for Moloney Murine Leukemia Virus (M-MLV) RT (Promega), 12.5µL of 
DEPC water, and 2µL of M-MLV RT (200U/µL; Promega). RT was replaced by DEPC for the 
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negative RT control. The RT reaction was carried out at 37oC for 1 hour. All temperature 
incubations were performed using a Bio-Rad Thermal Cycler (S1000 or MJ Mini). 
2.3.4 – RT-PCR and Gel Electrophoresis 
Polymerase chain reaction (PCR) reactions had a total volume of 25µL and contained 
4ng/µL cDNA, autoclaved MilliQ water, 5µL of 5x Green GoTaq flexi reaction buffer (Promega), 
1.5mM magnesium chloride (MgCl2; Promega), 200µM dNTPs, 2ng/µL of forward and reverse 
primers (Sigma-Aldrich), and GoTaq flexi DNA polymerase (5U/µL; Promega). Negative RT, and 
the no template (water) controls were also included in the PCR runs by substituting the cDNA 
volume with the respective control input. Primers were resuspended in 10mM Tris (pH = 8.0). 
Temperature changes were achieved using a Bio-Rad Thermal Cycler (S1000 or MJ Mini). 
Renalase primers were designed to bind its two main transcript variants (hRenalase1 and 
hRenalase2). Primer design was carried out using the National Center for Biotechnology 
Information (NCBI) primer-BLAST software and the Integrated DNA Technologies (IDT) 
oligoanalyzer tool. All primer sequences, cycle numbers, and annealing temperatures are shown 
in Table 2. The target genes of this study correspond to renalase (Rnls), EGR-1 (Egr1), GR 
(Nr3c1), HIF1α (Hif1a), PAH (Pah), TH (Th), DBH (Dbh), intronless and intron-retaining PNMT 
(Pnmt), and 28s RNA (Rn28s1). Visualization of PCR products was completed using the same 
electrophoresis conditions as the RNA integrity protocol except that a 2% TAE (tris-acetate-
EDTA) gel was immersed in TAE buffer. TAE buffer was made using MilliQ water containing 
40mM Tris base, 20mM acetic acid, and 1mM EDTA. 10µL of PCR product, negative RT control, 
or water control were loaded into each well. 
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2.3.5 – Densitometry 
 PCR products were visualized using a Bio-Rad UV ChemiDoc analyzer and the Quantity 
One software. Flat-field correction was enabled for all gels and exposure times were maximized 
until brightest bands were just under saturated density. Adjusted volumes using the “Local” 
function were used for the final density measurements. All measurements were normalized to the 
28s gene.
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Table 2: Primer specifications and conditions for RT-PCR. 
Gene Name; 
Accession 
Number 
Forward Primer Sequence (5’-3’) Reverse Primer Sequence (5’-3’) 
# of 
Cycles 
Annealing 
Temperature 
(oC) 
Amplicon 
Size (bp) 
Rnls; 
NM_001014167.1 
GATAACAAGTGGGAAGTCTC CATAAAAGAGGCCCAGAGC 30 54 187 
Egr1; 
NM_012551.2 
TTTCCACAACAACAGGGAGAC CTCAACAGGGCAAGCATACG 35 58 261 
Nr3c1; 
NM_012576.2 
CTCTGGAGGACAGATGTACCA GCTTACATCTGGTCTCATTCC 28 58 232 
Hif1a; 
NM_024359.1 
GGTGCTAACAGATGATGGTGA CTGGGCCATTTCTGTGTGTAAGC 27 58 161 
Pah; 
NM_012619.2 
GCTGCTAAGCTAGACACCTCA CTTGTTTCCTGCCCAAAGTCT 31 58 105 
Th; 
NM_012740.3 
GCGACAGAGTCTCATCGAGGAT GGCACCTCGAAGCGCACAAAA 20 52 303 
Dbh; 
NM_013158.2 
TTCCCCATGTTCAACGGACC AGCTGTGTAGTGTAGACGGATGC 28 58 240 
Pnmt; 
NM_031526.1 
CAGACTTCTTGGAGGTCAACCG AGCAGCGTCGTGATATGATAC 35 58 426/316 
Rn28s1; 
NR_046246 
AGGGATAACTGGCTTGTGGC TAAACCCAGCTCACGTTCCC 18 58 143 
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2.4 – Western Blotting 
2.4.1 – Protein Extraction 
Immediately after treatment, cells were washed twice in ice-cold PBS. 250µL of cold 
radioimmunoprecipitation assay (RIPA) buffer was added per 35mm well. RIPA was made using 
25 mM Tris base, 150 mM NaCl, 1% sodium deoxycholate (Sigma-Aldrich), 1% 
nonyl phenoxypolyethoxylethanol 40 (NP-40; Sigma-Aldrich), 0.1% sodium dodecyl sulphate 
(SDS; ThermoFisher), 2 mM EDTA, 0.5 mM phenylmethylsulphonyl fluoride (PMSF; Sigma-
Aldrich), cOmplete Mini protease inhibitor cocktail tablet (1 tablet per 10mL; Roche), and 
hydrochloric acid (HCl)/sodium hydroxide (NaOH) to make a pH of 7.6. Cells were incubated on 
ice on a shaker for 10min and then centrifuged for 20min at 12 000 x g at 4oC. Supernatants were 
collected and stored at -20oC for short-term storage or -80oC for long term storage. In the single 
case for HIF1α protein, a nuclear extraction was performed instead of RIPA lysis. For nuclear 
extraction, cells were first washed twice with cold PBS immediately after treatment. Subsequently, 
cells were scraped, collected into microcentrifuge tubes with 1mL of cold PBS, and centrifuged at 
13 000 x g for 10s at 4oC. The pellet was incubated for 10min on ice in 200μL of lysis buffer A, 
which contained 10mM 4-(2-hydroxyethyl)-1-piperazineethanesulphonic acid-potassium 
hydroxide (Hepes-KOH; EMD/MilliPore), 1.5mM MgCl2 (Sigma-Aldrich), 10mM KCl, 0.5mM 
dithiothreitol (DTT; ThermoFisher), 0.2mM PMSF (Pierce, Waltham, MA), and 20μL of 1x 
protease inhibitor cocktail (Sigma-Aldrich). Next, samples were force-ejected 10 times through a 
22-gauge needle, vortexed, and centrifuged at 13 000 x g, as before. The following pellet was 
placed on ice for 20min in 50μL of lysis buffer C, which contained 20mM Hepes-KOH, 1.5mM 
MgCl2, 420mM NaCl, 25% glycerol, 0.2mM EDTA, 0.5mM DTT, 0.2mM PMSF, and 20μL of 
protease inhibitor cocktail. Another centrifugation at 13 000 x g (4oC) was carried out for 2min 
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and nuclear extracts were collected from the supernatant. Finally, protein extraction from 
WKY/SHR adrenals was performed using Qiagen’s AllPrep DNA/RNA/Protein Mini Kit as per 
the manufacturer’s instructions.  
2.4.2 – Protein Quantification 
 Protein concentrations were estimated using standard Bradford or bicinchoninic acid 
(BCA) assay procedures. BCA assays were performed for adrenal protein and PC12 protein from 
time-variable treatments with PMA, Dex, Fsk, and NGF. Bradford standards were prepared using 
immunoglobulin G protein (IgG; Sigma-Aldrich) and MilliQ water. 250μL of 1x Bradford reagent 
(BioRad) was added to each well and incubated at room temperature for 5min. For the BCA assays, 
all sample and standard preparation were performed as per the manufacturer’s instructions 
(Pierce). Bradford assay samples/standards were read at a wavelength of 595nm, while BCA assay 
samples/standards were read at 562nm. Absorbance readings were measured using a PowerWave 
XS spectrophotometer and KC-4 software by BioTek (Winooski, VT). Two technical replicates 
were completed for the quantification of all standards and samples. 
2.4.3 – Gel Casting 
 Polyacrylamide gel electrophoresis (PAGE) was performed using the Mini-PROTEAN 
Tetra cell kit and instructions from BioRad. All solutions were made according to the available 
protocol, with the exception that a 29:1 acrylamide/bis-acrylamide ratio was used instead of 37.5:1. 
Acrylamide/bis-acrylamide, ammonium persulphate (APS), tetramethylethylenediamine 
(TEMED), and glycine were purchased from ThermoFisher. Spacer plate thickness in all cases 
was 1.5mm. 10% resolving gels were layered with 200µL of butanol (Sigma-Aldrich) saturated 
with water and left to polymerize for 30min. Water-saturated butanol was thoroughly washed out 
with distilled water, 4% stacking gels were poured, 15-well combs were set up, and polymerization 
took place for 25min.  
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2.4.4 – Sample Loading and Gel Electrophoresis 
 A load volume of 30µL was used to help prevent sample loss. RIPA (or lysis buffer C) was 
used to adjust sample volume. Samples contained 20µg of protein and 5µL of 6x loading dye 
(made from 300mM Tris base, 12% SDS, 12mM EDTA, 6% β-mercaptoethanol (BME; Sigma-
Aldrich), 60% glycerol, and 6% bromophenol blue). Prior to loading, samples were denatured at 
95oC for 5min using a Digital Dry Block Heater from VWR (Radnor, PA). After assembly of the 
gel in the apparatus with running buffer, excess salt in the newly-formed wells was washed and 
cleared using a 23-gauge needle. 10µL of the 100kDa protein ladder from Promega was also 
loaded. Using a BioRad’s PowerPac, electrophoresis through the stacking gel was completed at 
75V. After the protein reached the resolving gel, the voltage was increased to 100V and remained 
for 2.5 hours. 
2.4.5 – Electrotransfer 
 All transfers were achieved using BioRad’s Mini Trans-Blot Cell System and the 
manufacturer’s instructions were followed. Methanol (Sigma-Aldrich) was added to the transfer 
buffer at a concentration of 20%. Transfer buffers were cooled to 4oC before use. Polyacrylamide 
gels were equilibrated in cold transfer buffer for 5min before transfer. Proteins were transferred 
onto a nitrocellulose membrane with a pore size of 0.2µm (Pall, Port Washington, NY). 3 filter 
papers were added outside and adjacent to the gel and membrane (6 papers total). Potential bubbles 
within the transfer sandwich were removed by rolling a pipette across the outer surface four times. 
After assembly of the apparatus, a PowerPac was set to 100V for 1 hour. Activation of the stir 
bead was performed using a VWR magnetic stirrer.   
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2.4.6 – Blocking and Antibody Incubation 
Washing procedures were performed using tris-buffered saline with tween-20 (TBS-T; 
20mM Tris HCl, 465mM NaCl, and 0.1% tween-20 (MP Biochemicals, Santa Ana, CA); pH = 
7.4). A blocking buffer was made using 5% instant skim milk powder (Carnation, Markham, ON) 
in TBS-T. Immediately after transfer, protein transfer quality was verified by incubating 
membranes with Ponceau S stain (0.1% Ponceau S (Sigma-Aldrich) and 5% acetic acid in MilliQ 
water) for 2min and destained with 0.1M NaOH and subsequent washes in distilled water. After 
destaining, membranes were placed in blocking buffer for 1 hour on a shaker with a medium speed 
setting and at room temperature. Before primary antibody incubation, membranes were washed in 
TBS-T four times (5min each) on the shaker with the same conditions as before. Primary antibodies 
were diluted in blocking buffer (containing 0.01% sodium azide (NaN3; Sigma-Aldrich) after first 
use) using the conditions provided in Table 3. Membranes were placed in excess primary antibody 
mixture and left on a Rocker II (Boekel, Feasterville, PA) at 4oC overnight. Between primary and 
secondary antibody incubations, four washes of the membrane were completed at 10min each. 
Secondary antibodies conjugated to horseradish peroxidase (HRP) were also diluted in blocking 
buffer (without NaN3) using the conditions listed in Table 3. Membranes were immersed in this 
mixture, placed on a rocker at room temperature, and left for 1 hour. Finally, before the enhanced 
chemiluminescence (ECL) reaction, membranes were washed (4 x 10min) on a shaker at room 
temperature.  
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Table 3: Antibody specifications and conditions for western blotting. 
Protein 
Specificity 
Antibody 
Type 
Host 
Animal 
Company; Catalogue 
# 
Lot # 
Dilution 
Ratio 
(Antibody:
Buffer) 
Glyceraldehyde 
3-phosphate 
dehydrogenase 
(GAPDH) 
Primary Mouse 
Abcam (Cambridge, 
UK); ab8245 
GR232949-
3 
1:10 000 
Proliferating 
cell nuclear 
antigen 
(PCNA) 
Primary Mouse 
Santa Cruz (Dallas, 
TX); sc-56 
A1113 1:500 
Hypoxia-
inducible factor 
1α (HIF1α) 
Primary Rabbit 
Novus (Littleton, CO); 
NB100-134 
M-3 1:1000 
Early growth 
response 
protein 1 
(EGR-1) 
Primary Rabbit Santa Cruz; sc-189 G2114 1:500 
Phospho-ser40 
tyrosine 
hydroxylase 
(TH) 
Primary Rabbit Novus; NB300-173  AJ0514y 1:4000 
Renalase 
(Rnls) 
Primary Rabbit Abcam; ab178700 
GR153391-
1 
1:2500 
Mouse IgG 
HRP-
conjugated 
secondary 
Donkey Santa Cruz; sc-2005 B2014 1:2000 
Rabbit IgG 
HRP-
conjugated 
secondary 
Goat Abcam; ab97051 
GR249836-
5 
1:5000 
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2.4.7 – Enhanced Chemiluminescence 
 A 1:1 ratio of ECL A and ECL B solutions was made immediately before the ECL reaction. 
ECL A solution contained 2.5mM luminol (Sigma-Aldrich), 0.4mM p-coumaric acid (Sigma-
Aldrich), and 0.1M Tris-HCl (from a solution with pH = 8.5) dissolved in MilliQ water. ECL B 
solution contained 8.2mM H2O2, and 0.1M Tris-HCl (pH = 8.5) dissolved in MilliQ water. 
Membranes were blot-dried on a clean plastic sheet and approximately 1.5mL of the ECL mixture 
was added to each membrane for 2min. The ECL mixture was quickly blot-dried after incubation 
and membranes were stored in clear plastic sheets for film exposure. Membranes were stored in a 
sealed plastic film at room temperature. 
2.4.8 – Film Exposure, Development, and Densitometry 
 In a darkroom, ThermoFisher CL-XPosure films were placed over membranes using an x-
ray cassette. Exposure times were chosen to allow bands to be just under saturation. Films were 
developed using a SRX 101A Konica Film Processor and reagents (Mississauga, ON) as per the 
manufacturer’s instructions. Band densities were analyzed using the Bio-Rad UV ChemiDoc 
analyzer and the Quantity One software as before. Protein quantities were normalized to 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) for cytosolic extractions or proliferating 
cell nuclear antigen (PCNA) for nuclear extractions.  
2.4.9 – Stripping Membranes 
 Membranes were stripped and reprobed up to 2 times after the first western blot procedure. 
Harsh stripping buffer was made with MilliQ water containing 2% SDS, 62.5mM Tris-HCl (from 
a solution with pH = 6.8), and 0.8% BME (as per Abcam’s instructions). Membranes were 
incubated with harsh stripping buffer in a sealed container for 30min. This incubation took place 
in a heated shaking water bath (Precision Series 51221080 from ThermoFisher) on low speed at 
50oC. Membranes were then rinsed 10 ten times with distilled water and washed 6 times (10min 
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each) in TBS-T on a shaker with moderate speed. Membranes were transferred to a new container 
and blocking, washing, and reprobing were carried out as before (starting with the first blocking 
step after Ponceau staining).  
2.5 – Statistical Analyses 
 All statistical analyses were performed using the GraphPad Prism software (La Jolla, CA). 
In all cases, mean, standard error of the mean (SEM), and interquartile range (IQR) were 
calculated. Outliers were considered when measurements were lower than the first quartile or 
higher than the third quartile by a magnitude greater than 1.5 x IQR. Differences between treatment 
durations and doses were analyzed using a one-way ANOVA with a post-hoc Tukey test. All other 
statistical analyses were performed using an unpaired, two-tailed t-test. Significant differences 
were considered where p ≤ 0.05. 
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3 – Results 
3.1 – Objective 1: Regulation of Renalase by Signal Activators of Catecholamine Biosynthesis 
 To complete the first objective of this study, renalase expression was analyzed after 
treatments of PC12 cells with Epi and 9 signal activators of CA biosynthesis. For most treatments, 
positive control genes (i.e. EGR-1, HIF1α, TH, and PNMT) were also analyzed to confirm 
activation of the particular intracellular signaling pathways. In all PCR analyses, two negative 
controls were included by substituting RT or cDNA with MilliQ water. As expected, all negative 
controls did not show DNA amplification following PCR.  
3.1.1 – Protein Kinase C Signaling 
Time-variable and dose-variable treatments of PC12 cells with PMA were performed for 
the activation of PKC mechanisms. Because EGR-1 expression is normally upregulated by PMA, 
it was measured to confirm PMA signals (Tai & Wong, 2003). EGR-1 mRNA and protein were 
upregulated after 1 hour (1.81-fold and 22.24-fold, respectively; p ≤ 0.001) and began reduction 
to baseline levels after 6 hours (Figures 8A and 8B). mRNA levels of EGR-1 were still 
significantly upregulated after 6 hours (1.38-fold; p ≤ 0.05) but not after 12 or 24 hours. EGR-1 
protein was still elevated after 6, 12, and 24 hours, but did not reach significance. Renalase mRNA 
and intracellular protein were detected in all treatment groups and controls, indicating that PC12 
cells express renalase. In Figure 8C it is shown that PMA signal activation reduced renalase mRNA 
after 6-hour treatments (0.71-fold; p ≤ 0.05) and significantly increased to normal levels from 6 to 
24 hours (1.35-fold; p ≤ 0.01). Renalase protein was unchanged by time-variable treatments of 
PMA. All PMA doses did not alter renalase mRNA levels. 
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Figure 8: Gene expression after time-variable and dose-variable treatments of PC12 cells with 
phorbol 12-myristate 13-acetate (PMA). Image shows mRNA and intracellular protein levels of 
early growth response protein 1 (EGR-1; A and B) and renalase (Rnls; C, D, and E) detected by 
RT-PCR and western blotting. Time-variable treatments used 80nM PMA and dose-variable 
treatments were 6 hours long. Images shown are representative gel bands of each treatment. Fold-
changes were normalized to untreated controls. mRNA and protein data were normalized to 28s 
RNA and glyceraldehyde 3-phosphate dehydrogenase (GAPDH), respectively. Data are presented 
as mean ± SEM (n = 3). *, **, and *** directly above bars indicate significance from untreated 
controls where p ≤ 0.05, p ≤ 0.01, and p ≤ 0.001, respectively (using ANOVA with a post-hoc 
Tukey test). All other significant differences between groups are bracketed. 
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3.1.2 – Glucocorticoid Signaling 
 To activate glucocorticoid signaling processes, Dex treatments were also performed on 
PC12 cells in a time-variable and dose-variable manner. The intronless form of PNMT mRNA is 
normally increased by Dex, and here, it was quantitated to confirm Dex activity (Figure 9A; K. T. 
Kim et al., 1993). This mechanism was confirmed, as intronless PNMT mRNA was upregulated 
after 6, 12, and 24 hours of Dex treatment (12.56-fold, 13.95-fold, and 9.34-fold, respectively; p 
≤ 0.001 in all cases). Dex did not show significant differences in intronless PNMT between 1-hour 
treatments and controls. Instead, the 1-hour treatment group was significantly different compared 
with the 6, 12, and 24-hour time points. TH activity is also increased by Dex signaling (Williams, 
Sandquist, Black, & Williams, 1981). Active TH protein (pSer40) was therefore analyzed after 
time-variable treatments with Dex (Figure 9B). This analysis revealed significantly increased 
pSer40 TH after 24 hours (2.78-fold; p ≤ 0.05). Renalase mRNA levels were unchanged after time-
variable or dose-variable treatments (Figures 9C and 9E). In contrast, renalase protein level (Figure 
9D) was higher in 24-hour treatments compared to 6 hours. (1.35-fold; p ≤ 0.01). However, no 
time-points had significantly different protein levels compared to controls. 
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Figure 9: Gene expression after time-variable and dose-variable treatments of PC12 cells with 
dexamethasone (Dex). Image shows mRNA levels of intronless phenylethanolamine N-
methyltransferase (PNMT; A) and renalase (Rnls; C). Image also shows intracellular protein levels 
of pSer40 tyrosine hydroxylase (TH; B) and renalase (Rnls; D and E) detected by RT-PCR and 
western blotting. Time-variable treatments used 1µM Dex and dose-variable treatments were 6 
hours long. Images shown are representative gel bands of each treatment. Fold-changes were 
normalized to untreated controls. mRNA and protein data were normalized to 28s RNA and 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), respectively. Data are presented as mean 
± SEM (n = 3). *, **, and *** directly above bars indicate significance from untreated controls 
where p ≤ 0.05, p ≤ 0.01, and p ≤ 0.001, respectively (using ANOVA with a post-hoc Tukey test). 
All other significant differences between groups are bracketed. 
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3.1.3 – Hypoxia-inducible Factor Signaling 
 To observe the influence of hypoxia signaling on renalase expression in PC12 cells, time-
variable and dose-variable treatments with CoCl2 were completed. Signal activation was 
confirmed by analyzing mRNA and protein levels of HIF1α. Cobalt binds directly to HIF1α and 
inhibits its degradation (Yuan et al., 2003). Without degradation, it localizes to the nucleus and 
acts as a TF. Therefore, an increase in HIF1α protein in the nucleus is characteristic of the signaling 
activities of CoCl2. Under different conditions of hypoxia, HIF1α mRNA has been shown to be 
unchanged or increased following cell treatment (Huang, Arany, Livingston, & Bunn, 1996; Tai 
et al., 2009). In this study, its mRNA was unchanged (Figure 10A), but nuclear protein levels were 
increased after 6 hours (3.46-fold; p ≤ 0.01; Figure 10B). Nevertheless, HIF1α mRNA was not 
analyzed after 24 hours and nuclear protein was not analyzed with time-variable treatments. 
Renalase mRNA levels were quantified after three separate experiments of CoCl2 treatments (one 
time-variable, one dose-variable, and one set of 24-hour treatments; Figures 10C, 10E, and 10D, 
respectively). No changes in renalase mRNA were observed in all treatments other than the 24-
hour treatment. After 24 hours of CoCl2 treatment, renalase mRNA was moderately downregulated 
(0.77-fold; p ≤ 0.05). Renalase protein was also quantified after 24-hour treatments with CoCl2 
(not shown). Due to high variability in the normalization protein, glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), no conclusive analysis could be performed on renalase protein 
regulation after CoCl2 treatment. 
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Figure 10: Gene expression after time-variable and dose-variable treatments of PC12 cells with 
cobalt chloride (CoCl2). Image shows mRNA and intracellular protein levels of nuclear hypoxia-
inducible factor 1α (nuclear HIF1α; A and B) and mRNA levels of renalase (Rnls; C, D, and E) 
detected by RT-PCR and western blotting. Time-variable treatments used 200µM CoCl2 and dose-
variable treatments were 6 hours long. Images shown are representative gel bands of each 
treatment. Fold-changes were normalized to untreated controls. mRNA and protein data were 
normalized to 28s RNA and proliferating cell nuclear antigen (PCNA), respectively. Data are 
presented as mean ± SEM (n = 3). * and ** directly above bars indicate significance from untreated 
controls where p ≤ 0.05 and p ≤ 0.01, respectively (using ANOVA with a post-hoc Tukey test).  
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3.1.4 – Protein Kinase A Signaling 
Next, renalase expression was determined following PKA activation by Fsk treatments. 
Confirmation of intracellular signaling was completed by analyzing the expression of EGR-1, 
which was previously shown to be quickly increased after Fsk treatment (Tai & Wong, 2003). 
Indeed, following 1-hour treatments with Fsk, EGR-1 mRNA was significantly upregulated by a 
factor of 1.50 (p ≤ 0.01; Figure 11A). There were no significant differences between controls and 
6, 12, or 24-hour Fsk treatments. EGR-1 protein was quantified after the same time-points and 
treatment conditions. There was no detectable EGR-1 protein in all treatment groups other than 1-
hour treatments. Despite this signal activation, neither renalase mRNA or protein were altered at 
the time-points investigated (Figures 11B and 11C).  
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Figure 11: Gene expression after time-variable treatments of PC12 cells with forskolin (Fsk; 
10µM). Image shows mRNA of early growth response protein 1 (EGR-1; A) and mRNA and 
intracellular protein levels of renalase (Rnls; B and C). Expression levels were detected by RT-
PCR and western blotting. Images shown are representative gel bands of each treatment. Fold-
changes were normalized to untreated controls. mRNA and protein data were normalized to 28s 
RNA and glyceraldehyde 3-phosphate dehydrogenase (GAPDH), respectively. Data are presented 
as mean ± SEM (n = 3). * and ** directly above bars indicate significance from untreated controls 
where p ≤ 0.05 and p ≤ 0.01, respectively (using ANOVA with a post-hoc Tukey test). All other 
significant differences between groups are bracketed. 
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3.1.5 – Epinephrine and Nicotine Treatment 
 24-hour treatments with Epi or Nic were performed for two reasons: to activate common 
signals of chromaffin cells, and to examine previously established regulating signals of renalase 
in PC12 cells (Sonawane et al., 2014). Because Epi autocrine and paracrine signaling pathways 
aren’t fully characterized in PC12 cells, mRNA levels of TH, intron-retaining PNMT, and 
intronless PNMT were analyzed. These genes were also used to confirm signal activations of Nic. 
After Epi treatments, mRNA levels showed downregulated TH (0.79-fold; p ≤ 0.05; Figure 12A), 
upregulated intron-retaining PNMT (2.56-fold; p ≤ 0.05; Figure 12B), and unaltered intronless 
PNMT (Figure 12C). Nic slightly increased TH mRNA (1.18-fold; p ≤ 0.05; Figure 12A), but 
didn’t change the level of PNMT transcript variants (Figures 12B and 12C). Likewise, renalase 
mRNA was unchanged after Nic and Epi treatments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
64 
 
 
Figure 12: mRNA levels after 24-hour treatments of PC12 cells with epinephrine (Epi; 200µM) 
and nicotine (Nic; 500µM). Top row shows mRNA levels of tyrosine hydroxylase (TH; A), intron-
retaining phenylethanolamine N-methyltransferase (PNMT; B) and intronless PNMT (C). Bottom 
row (D) shows mRNA levels of renalase (Rnls). Expression levels were detected by RT-PCR. 
Images shown are representative gel bands of each treatment. Fold-changes were normalized to 
untreated controls. mRNA levels were normalized to 28s RNA. Data are presented as mean ± SEM 
(n = 3). * indicates significance from untreated controls where p ≤ 0.05 (using a two-tailed, 
unpaired t-test).  
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3.1.6 – Pituitary Adenylate Cyclase-Activating Polypeptide, Hydrogen Peroxide, and 
Angiotensin II Treatment 
 Additional activators of CA biosynthesis, PACAP, H2O2, and Ang II, were investigated to 
determine if their intracellular signaling pathways also regulate renalase. Two treatment conditions 
were used for PACAP to stimulate different intracellular signals that include PKA and PKC 
activation (Tai et al., 2010; Taupenot, Mahata, Mahata, & O’Connor, 1999; Vaudry et al., 2002). 
One gene that is regulated by PACAP and Ang II is PNMT (Cahill, Eertmoed, Mangoura, & 
Perlman, 2002; Tai et al., 2010). H2O2 could potentially regulate PNMT by inhibiting HIF1α 
degradation (Qutub & Popel, 2008). Thus, intron-retaining and intronless PNMT mRNA levels 
were quantified following treatments. There were no significant differences in either of the PNMT 
mRNA variants (not shown). No changes in renalase mRNA or protein were observed for all 
treatment conditions analyzed (Figures 13A – 13D).  
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Figure 13: Renalase (Rnls) gene expression after treatments of PC12 cells with pituitary adenylate 
cyclase-activating polypeptide (PACAP), hydrogen peroxide (H2O2), and angiotensin II (Ang II). 
Top row shows mRNA levels detected by RT-PCR and bottom row shows intracellular protein 
levels detected by western blotting. PACAP treatments (A and C) were performed for 45min at 
10nM or 6 hours at 100nM. H2O2 treatments (B and D) were performed for 30min at 500µM. Ang 
II treatments (B) were performed for 6 hours at 100nM. Images shown are representative gel bands 
of each treatment. Fold-changes were normalized to untreated controls. mRNA and protein levels 
were normalized to 28s RNA and glyceraldehyde 3-phosphate dehydrogenase (GAPDH), 
respectively. Data are presented as mean ± SEM (n = 3). No significant differences between groups 
were revealed using a two-tailed, unpaired t-test.  
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3.1.7 – Nerve Growth Factor Treatment 
The last activator of CA biosynthesis that was used for the treatment of PC12 cells was 
NGF. Because NGF induces time-dependent increases in EGR-1 expression, this gene was used 
to confirm intracellular signal activation (Tai et al., 2006). In the present study, time-variable 
treatments with NGF increased EGR-1 mRNA levels at all time points investigated. The highest 
increase in EGR-1 mRNA occurred with 1-hour treatments (1.79-fold; p ≤ 0.001) and significant 
decreases from 1-hour treatments were observed with 6, 12, and 24-hour NGF incubations (Figure 
14A). Nevertheless, all NGF treatment durations resulted in upregulated EGR-1 mRNA. A similar 
pattern was observed with EGR-1 protein. The highest increase in protein occurred after 1 hour 
(5.54-fold; p ≤ 0.001) and levels were significantly reduced from the 1-hour time-point with 6, 12, 
and 24-hour treatments (Figure 14B). When analyzing renalase expression, there were no 
significant changes after NGF treatment at the mRNA or protein level (Figures 14C and 14D).  
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Figure 14: Gene expression after time-variable treatments of PC12 cells with nerve growth factor 
(NGF; 500pM). Image shows mRNA and intracellular protein levels of early growth response 
protein 1 (EGR-1; A and B) and renalase (Rnls; C and D) detected by RT-PCR and western 
blotting. Images shown are representative gel bands of each treatment. Fold-changes were 
normalized to untreated controls. mRNA and protein data were normalized to 28s RNA and 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), respectively. Data are presented as mean 
± SEM (n = 3). *, **, and *** indicate significance from untreated controls where p ≤ 0.05, p ≤ 
0.01, and p ≤ 0.001, respectively (using ANOVA with a post-hoc Tukey test). All other significant 
differences between groups are bracketed. 
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3.2 – Objective 2: Regulation of Catecholamine Synthesis by Renalase 
3.2.1 – Renalase Peptide-220 Treatment 
 For the completion of the second objective, mRNA levels of CA-biosynthesizing enzymes 
were quantitated following dose-variable treatments of PC12 cells with the renalase signaling 
peptide, RP-220. Dex treatment was also included with or without the RP-220 treatments. Dex 
alone was used as a positive control to detect changes in CA biosynthesizing enzymes. Dex 
treatment, added in combination with RP-220, was performed to find potential protective effects 
of RP-220 on the Dex response. GR mRNA was also analyzed to determine if potential reductions 
to the CA-biosynthesis enzymes would be due to the expression of this central TF in the Dex 
response. To account for trace amounts of acetonitrile in the RP-220 solvent, extra control groups 
were included that contained acetonitrile alone, or acetonitrile with Dex. For all genes, there were 
no significant changes with the addition of acetonitrile. The TF, GR, as well as PAH did not show 
significant alterations in mRNA levels for all treatment groups (Figures 15A and 15B). TH mRNA 
analysis revealed a characteristic Dex-dependent upregulation (1.55-fold; p ≤ 0.001; Figure 15C). 
Dex, in combination with RP-220, did not show altered TH regulation when compared with Dex 
alone. RP-220 itself did not induce any changes to TH regulation. All three treatment groups 
containing Dex had significantly higher TH mRNA levels compared with untreated controls and 
RP-220 groups (p ≤ 0.001). For DBH, RP-220 alone did not alter mRNA levels at both 
concentrations (Figure 15D). mRNA levels, when compared to the control group, were 
significantly increased with Dex treatment (1.22-fold; p ≤ 0.05) and with Dex and 8.5µM RP-220 
(1.23-fold; p ≤ 0.05). All groups containing Dex had significantly higher DBH mRNA compared 
to the 1.5µM RP-220 group. 8.5µM RP-220 treatment was not significantly different to the Dex 
groups. Regarding PNMT, Dex treatment, with or without RP-220, showed complete loss of 
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intron-retaining mRNA and significant increases in intronless mRNA, when compared to controls 
(Figures 15E and 15F). Both RP-220 concentrations resulted in a slight increase in intron-retaining 
mRNA, but these changes were not significant. mRNA levels of intron-retaining and intronless 
PNMT were significantly different between the RP-220 groups and all three Dex groups (p ≤ 0.01). 
No differences were observed between Dex and Dex with RP-220 for both PNMT variants. 
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Figure 15: mRNA levels of catecholamine-biosynthesizing proteins after renalase peptide (RP-
220; P) treatments with and without dexamethasone (Dex; D). Image shows mRNA levels of 
glucocorticoid receptor (GR; A), phenylalanine hydroxylase (PAH; B), tyrosine hydroxylase (TH; 
C), dopamine β-hydroxylase (DBH; D), intron-retaining phenylethanolamine N-methyltransferase 
(PNMT; E) and intronless PNMT (F). mRNA levels were detected by RT-PCR. RP-220 treatments 
were 24 hours long at variable doses. Dex treatments were performed 6 hours before the end of 
RP-220 treatments and at a concentration of 1µM. Images shown are representative gel bands of 
each treatment. Fold-changes were normalized to untreated controls. mRNA data were normalized 
to 28s RNA. Data are presented as mean ± SEM (n = 3). *, **, and *** indicate significance from 
untreated controls where p ≤ 0.05, p ≤ 0.01, and p ≤ 0.001, respectively (using ANOVA with a 
post-hoc Tukey test). All other significant differences between groups are bracketed. 
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3.2.2 – Renalase Treatment 
Furthermore, mRNA levels of CA-biosynthesizing enzymes were quantified following 
dose-variable treatments with recombinant renalase in PC12 cells. Like the RP-220 treatments, 
Dex was used as a treatment alone, or in combination with two concentrations of recombinant 
renalase. Trace amounts of urea and glycerol in the renalase solvent were accounted for by 
including these in control groups +/- Dex. The inclusion of urea and glycerol did not have any 
effects on gene mRNA. GR and PAH did not show any changes in mRNA levels with all treatment 
conditions (Figures 16A and 16B). TH mRNA was upregulated with Dex treatment (1.55-fold; p 
≤ 0.001; Figure 16C). There were no differences between Dex in combination with renalase and 
Dex alone. TH regulation was unchanged by both concentrations of renalase. The three groups 
containing Dex showed significantly increased TH mRNA when compared with controls or 
renalase treatments (p ≤ 0.01). In contrast with RP-220 DBH mRNA levels were not significantly 
different between groups (Figure 16D). A partial factor for this finding is that the variability within 
groups was slightly higher than with the RP-220 treatments, thus making the ANOVA just under 
significance (p = 0.087). Very similar patterns of PNMT mRNA regulation were observed between 
RP-220 and renalase treatments. Again, Dex alone and Dex in combination with renalase revealed 
a loss of intron-retaining mRNA and increases in intronless mRNA, compared to controls (Figures 
16E and 16F). 50nM and 250nM renalase treatments appeared to increase intron-retaining mRNA, 
but these changes were not significant. For intron-retaining and intronless PNMT mRNA, there 
were significant differences between both renalase groups and all three Dex groups (p ≤ 0.01). No 
differences were observed between Dex and Dex with renalase for both PNMT variants. 
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Figure 16: mRNA levels of catecholamine-biosynthesizing proteins after recombinant renalase 
(Rnls; R) treatments with and without dexamethasone (Dex; D). Image shows mRNA levels of 
glucocorticoid receptor (GR; A), phenylalanine hydroxylase (PAH; B), tyrosine hydroxylase (TH; 
C), dopamine β-hydroxylase (DBH; D), intron-retaining phenylethanolamine N-methyltransferase 
(PNMT; E) and intronless PNMT (F). mRNA levels were detected by RT-PCR. Rnls treatments 
were 24 hours long at variable doses. Dex treatments were performed 6 hours before the end of 
Rnls treatments and at a concentration of 1µM. Images shown are representative gel bands of each 
treatment. Fold-changes were normalized to untreated controls. mRNA data were normalized to 
28s RNA. Data are presented as mean ± SEM (n = 3). *, **, and *** indicate significance from 
untreated controls where p ≤ 0.05, p ≤ 0.01, and p ≤ 0.001, respectively (using ANOVA with a 
post-hoc Tukey test). All other significant differences between groups are bracketed. 
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3.3 – Objective 3: Expression of Renalase in the Adrenal Gland of the SHR 
The third objective of this study investigated the expression of renalase in adrenal glands 
from WKYs and SHRs. At the mRNA level, there was a clear upregulation of renalase in adrenal 
glands from SHRs (1.43-fold; p ≤ 0.001; Figure 17). There was also a notably small variability 
between animals (SEM = 0.022 for WKYs; SEM = 0.031 for SHRs). Surprisingly, the variability 
of renalase protein levels was exceptionally higher than that of mRNA (SEM = 0.42 for WKYs; 
SEM = 0.27 for SHRs). The main contributing factor of this large variability was the robust 
increases of renalase protein in the adrenals of certain animals (Figure 18). These animals with 
robust increases were not limited to a particular animal model. This variability was only observed 
with renalase, and not with the normalization protein, GAPDH. 
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Figure 17: Renalase (Rnls) mRNA levels in the adrenal glands of Wistar-Kyoto rats (WKYs) and 
spontaneously hypertensive rats (SHRs). mRNA levels were detected by RT-PCR. Images shown 
are representative gel bands of each animal group. Fold-changes were normalized to WKY 
controls. mRNA data were normalized to 28s RNA. Data are presented as mean ± SEM (n = 4). 
*** indicates significance from WKYs where p ≤ 0.001 (using a two-tailed, unpaired t-test). 
 
 
Figure 18: Renalase (Rnls) protein levels in individual adrenal glands from Wistar-Kyoto rats 
(WKYs) and spontaneously hypertensive rats (SHRs). Protein levels were detected by western 
blotting. Images shown are representative gel bands from each animal. Protein levels are compared 
to glyceraldehyde 3-phosphate dehydrogenase (GAPDH).  
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4 – Discussion 
 Although there is opposing evidence to renalase’s ability to oxidize CAs, many studies 
have shown protective effects of renalase on CA levels and hypertension (Desir, Wang, et al., 
2012). These findings suggest that renalase regulates CAs with an alternative regulatory 
mechanism. Since its discovery in 2005, no studies have investigated the role of renalase in the 
adrenal medulla, which is the largest producer of circulating CAs. Yet, renalase’s expression in 
the adrenal gland is among the highest in the body (Zhou et al., 2013). Hence, it is a strong 
possibility that renalase signaling in the adrenal medulla is regulated by paracrine, autocrine, and 
endocrine mechanisms. This study presents the first investigation of the potential role of renalase 
in the adrenal medulla.  
 These results present several novel findings. First, the PC12 cell model continuously 
expresses the renalase gene, with its mRNA and protein being easily detectable in all treatment 
groups and controls. With this finding, it is now known that the gene expression profile of 
undifferentiated pheochromocytoma cells do not strongly suppress renalase expression (Hopewell 
& Ziff, 1995; Jarrott & Louis, 1977). Second, renalase is not robustly regulated by the cell signals 
and conditions tested in objective 1 of this study (Figures 8-14). Despite there being time-
dependent variations in renalase expression by PMA, Dex, and CoCl2, all fold-changes were low 
and possibly have only minor effects at the physiological level (Figures 8C, 9D, and 10D). Another 
novel finding was that renalase and its peptide, RP-220, do not alter the expression of CA-
biosynthesizing enzymes in PC12 cells (Figures 15 and 16). Still, it is possible that renalase is part 
of a negative feedback mechanism that acts upon other areas of CA regulation (i.e. CA 
storage/reuptake, secretion, or COMT and MAO-dependent metabolism). The last major finding 
of this study was the identification of altered regulations of renalase in vivo. In the adrenal glands 
79 
 
of SHRs, renalase mRNA was significantly upregulated (Figure 17). At the protein level, renalase 
could have been increased in certain animals from WKYs and SHRs (Figure 18), but the 
mechanism for this regulation remains to be elucidated.  
 This experiment presents the first comprehensive examination of renalase regulation in 
PC12 cells. Its regulation was examined following 10 known extracellular and intracellular signal 
activators within this cell line. Renalase regulation, in any cell or animal model, has not been 
previously examined following Dex, PACAP, ROS, NGF, or Fsk treatment. The other 5 cell 
signals have been previously used in other cell lines, but mostly showed different results than the 
present study.  
The results of objective 1 show the novel finding that PKC signaling in PC12 cells does 
not alter renalase expression. Previously, S. Wang et al. showed that in renal proximal tubule cells 
(RPTs), the activator of PKC, PMA, increased renalase protein after 24 hours (2014). This 
detection may or may not have been renalase because of the molecular weight of the protein that 
was analyzed (70kDa, instead of the normal 42kDa for renalase). If renalase is altered by PMA in 
RPTs, the present study suggests that renalase regulation is likely different in PC12 cells and 
possibly chromaffin cells, suggesting a tissue-specific response. Our study demonstrated that 
renalase expression was not altered by PMA using similar concentrations and time points as the 
RPT treatments. Renalase mRNA could be temporarily reduced after 6 hours of PMA treatment 
(Figure 8C), but the same dose and time point from the dose-variable treatments did not replicate 
this reduction (Figure 8E). PMA only activates DAG and a limited number of PKC subtypes 
(Figure 3; Wu-Zhang & Newton, 2013). From this experiment, it can only be stated that DAG-
activated PKC isoforms do not regulate renalase independently in PC12 cells. To account for more 
isoforms of PKC, Ang II treatment was performed. AT1R receptors can activate more PKC 
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subtypes than PMA (via IP3 and intracellular Ca2+ signaling; Gwathmey et al., 2012; Wu-Zhang 
& Newton, 2013). In a previous study, it was suggested that the RAS may not play a role in 
regulating renalase (Y. Wang et al., 2015). Results of the present study supported this previous 
finding as Ang II did not alter mRNA levels of renalase (Figure 13B). Taken together, these 
findings provide evidence that most PKC mechanisms do not regulate renalase mRNA levels 
independently. 
Alternatively, renalase regulation might require PKA activation. The effects of PKA 
activation were investigated by treating PC12 cells with Fsk, which activates this pathway by direct 
interaction with AC (Seamon & Daly, 1981). Nevertheless, Fsk did not alter renalase expression 
(Figures 11B and 11C). Nic is another activator of the PKA pathway, in addition to its ability to 
increase intracellular Ca2+ (Madhok, Matta, & Sharp, 1995; Sala et al., 2007). Because renalase 
was unchanged following Nic treatment (Figure 12D), this study demonstrates that PKA in 
combination with calcium signaling is another pathway that does not regulate renalase in this cell 
type. Similar to CA-biosynthesizing enzymes, renalase might require both PKC and PKA signaling 
for increased expression in PC12 cells (Tai & Wong, 2003). Evidence that does not support this 
idea was provided by treatments with PACAP and NGF, which have complex signaling pathways 
that can activate PKA and PKC (Kalman, Wong, Horvai, Cline, & O’Lague, 1990; Tai et al., 
2006). Results of our study show that time-variable and dose-variable treatments of PC12 cells 
with PACAP or NGF did not induce changes to renalase expression (Figures 13 and 14). The 
findings from NGF treatments additionally indicate that renalase expression changes are not 
involved with PKB pathways and the neuronal differentiation process. Overall, these results show 
that the PKA pathway, whether independently activated or in combination with other protein 
kinase pathways, does not regulate renalase in PC12 cells. 
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Another novel finding was that HIF1α activation and ROS signaling in PC12 cells could 
have a small influence on renalase mRNA levels. One previous study showed that 200µM CoCl2 
treatment of cardiomyocytes for 24 hours induced increases in renalase mRNA via HIF1α 
activation (Du et al., 2015). Our results show that PC12 cells treated with CoCl2 can increase 
HIF1α activation, but do not alter renalase mRNA levels at early time points or with higher 
concentrations (Figures 10B, 10C, and 10E). Using the same treatment conditions as Du et al., 
renalase mRNA levels were slightly decreased, instead of being increased (Figure 10D). Analysis 
of renalase protein levels after 24-hour treatments with CoCl2 should be performed to validate the 
effects of CoCl2 on renalase expression. Since ROS is produced by CoCl2, H2O2 treatments were 
included to detect potential changes in renalase expression (Crispo et al., 2011). Following this 
treatment, no changes in renalase expression were observed (Figures 13B and 13D). Therefore, 
H2O2-mediated ROS, like CoCl2, may not regulate renalase in this cell line. AT1Rs can also 
increase H2O2, indicating that our results from Ang II treatment support the notion that this form 
of ROS does not alter renalase expression in this cell model at the times and concentrations 
analyzed (Anupama et al., 2016). Other ROS like superoxides, nitric oxides, and hydroxyl radicals 
should also be investigated for potential regulation of renalase. Although these results provide 
evidence that CoCl2 downregulates renalase mRNA in PC12 cells, it is still unknown whether 
HIF1α, or ROS species (other than H2O2) are responsible for this regulation. 
Moreover, increases in renalase mRNA after Epi and Nic treatment of human embryonic 
kidney-293 (HEK-293) cells were not replicated in PC12 cells using the same treatment conditions 
(Figure 12D; Sonawane et al., 2014). Under certain conditions, Epi can activate SP1, and Nic can 
activate STAT3 and SP1. Both of these TFs have binding sites in the renalase promoter (Figure 
7). Previous studies have established that Nic induces PKA activation, suggesting that SP1 is also 
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activated (Madhok et al., 1995). If renalase expression was unchanged, SP1-mediated renalase 
regulation could require a coactivator. No change with Epi treatment is most likely due to a 
specialized adrenoceptor expression profile in PC12 and chromaffin cells (one that enhances α2 
activity). On the other hand, HEK-293 cells abundantly express α1 adrenoceptors (specifically, the 
α1B subtype), which could be why Sonawane et al. observed upregulation of renalase following 
Epi treatment (Atwood, Lopez, Wager-Miller, Mackie, & Straiker, 2011).  
Finally, the glucocorticoid signaling pathway was induced by treating PC12 cells with the 
synthetic glucocorticoid, Dex. This pathway is one of the most important signaling mechanisms in 
chromaffin cells because of the proximity of these cells to the adrenal cortex. Under the conditions 
of the present study, it does not appear that Dex can robustly regulate renalase mRNA or protein 
levels (Figures 9C and 9D). Although no studies have analyzed the effects of Dex treatment on 
renalase regulation, Dex could be a regulator of miRNA-29b, which can downregulate renalase 
mRNA (Deng, Tufan, Raza, Jones, & Zhu, 2016; Kalyani et al., 2015). Although renalase mRNA 
levels were unchanged after Dex treatment, miRNA-29b could be a potential mechanism for why 
renalase protein was slightly altered in a time-dependent manner. 
The minimal renalase regulation observed in this study provides insight for its regulation 
across numerous tissues. PC12 cells, being derived from rat pheochromocytoma tissue, are among 
the few in vitro cell models of chromaffin cells (Greene & Tischler, 1976). If the PC12 cell model 
accurately represents regulation of renalase in chromaffin cells, these results suggest that 
renalase’s regulation in the adrenal medulla is different from other tissues. One explanation for 
renalase’s sustained expression is because of the implications of autocrine or paracrine signaling 
by renalase. If renalase is increased by synthesis-activating signals, as the hypothesis suggests, its 
autocrine or paracrine signaling could immediately reduce the effect of the original signal. Because 
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the findings in this study suggest that renalase is not increased in chromaffin cells by these 
synthesis-activating signals, it could be that other endocrine tissues are responsible for the 
regulation of renalase in the blood. In other words, the negative feedback mechanism could still 
exist, but the regulation of renalase would occur in tissues other than chromaffin cells. Restricting 
renalase expression in chromaffin cells could allow for stronger SA activity, while still allowing 
for a trans-activated negative feedback mechanism. 
If renalase does regulate CAs in the adrenal medulla, the findings of this study indicate that 
the inhibition of CA-biosynthesizing enzymes may not be an effect of renalase signaling. Using 
both the signaling peptide, RP-220, and recombinant renalase to treat PC12 cells in a dose-variable 
manner, no changes were detected in the mRNA levels of PAH, TH, DBH, and intron-retaining or 
intronless PNMT (Figures 15 and 16). As a positive control, Dex treatments were performed and 
expected increases in TH, DBH, and PNMT mRNA were observed. Because renalase’s mechanism 
of action could be to attenuate Dex/cortisol-induced CA biosynthesis upregulation, additional 
groups of cells were exposed Dex during the last 6 hours of RP-220 or recombinant renalase 
treatment. The results of this study demonstrate that renalase does not attenuate the Dex/cortisol-
induced increases of TH, DBH, or PNMT mRNA (Figures 15 and 16). Without any 
downregulations in these enzymes being found, it is expected that GR mRNA was unchanged after 
renalase treatment (Figures 15A and 16A). The analysis of this TF was performed because it would 
also strongly inhibit the Dex/cortisol response if downregulated. Dex did not induce upregulation 
of GR because it mainly acts as a dissociating factor for the inactive HSP-GR complex (Drouin et 
al., 1992). PAH was also unchanged by renalase or Dex (Figures 15B and 16B). However, this 
enzyme is not necessary for de novo CA biosynthesis and its tissue expression levels suggest that 
this step is mainly performed by the liver (Uhlen et al., 2015). Future experiments should 
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investigate if renalase attenuates the actions of other mechanisms that increase CA activity, such 
as CA vesicular storage, uptake, and secretion. Renalase treatment could also be performed to 
determine if renalase increases the expression of CA-metabolizing enzymes (e.g. MAOs and 
COMTs). 
As for the expression of renalase in SHR and WKY adrenals, there were several important 
findings that provide a clue for the role of renalase in this tissue. First, it appears that an unknown 
genetic factor results in renalase mRNA being consistently elevated in the SHR (Figure 17). SHRs 
have elevated CAs in the blood, partially due to upregulated CA-biosynthesizing enzymes in the 
adrenal gland (Nguyen et al., 2009). Thus, renalase mRNA could be increased directly by CAs or 
by similar genetic factors that increase CA-biosynthesis in the SHR. Because renalase mRNA was 
stable in PC12 cells, the increase in renalase mRNA could have occurred in the adrenal cortex by 
the same signal activators used in objective 1. It is also possible renalase regulation was due to 
other unknown phenotypic differences in the SHR. Upregulated renalase mRNA cannot be 
generalized to other tissues because it was previously shown that SHRs also have lower renalase 
mRNA in the brain and lower renalase protein in plasma (Fedchenko et al., 2013; Jiang et al., 
2012). Our investigation of renalase protein levels in the adrenal glands provides the first set of 
evidence that renalase could play a large role in the adrenal gland. When protein levels were 
normalized to GAPDH, large differences in renalase protein levels were observed in various 
WKYs and SHRs (Figure 18). Renalase protein, when compared with its respective mRNA, 
suggests a potential post-translational or proteolytic mechanism of renalase regulation. If such a 
mechanism exists, its regulation of renalase could be part of normal physiology, because both 
normotensive and hypertensive animals exhibited high variation in renalase protein levels. 
Considering that our methods were designed to reduce extraneous variables between rats, the 
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unknown signal activator of renalase regulation is likely difficult to keep consistent between 
animals. Therefore, the unknown regulator of renalase could be a fast-acting or circadian signal. 
Adrenocorticotropic hormone (ACTH) is an example of such signal that can be fast-acting and 
involved with circadian rhythms (Mohn et al., 2005; Park et al., 2013).  
 Despite the novelty of these findings, the central hypothesis was not supported. Originally, 
it was proposed that renalase downregulates CA-biosynthesizing enzymes as part of a negative 
feedback mechanism in the adrenal medulla. For renalase to be part of this feedback mechanism, 
its expression would have to be increased after the upregulation of CA biosynthesis. Because there 
are many ways for CA biosynthesis to be regulated, multiple signaling pathways were used to 
detect this increase (e.g. PKC, PKA, cortisol, and hypoxia signaling). So far, there is no evidence 
to show that renalase is upregulated by the same signals that activate CA biosynthesis. However, 
the number of signaling mechanisms analyzed in this study is limited and there are other cell 
treatments still to be performed that could regulate CA biosynthesis and renalase together. One 
example of a treatment that should be investigated is the use of multiple signal activators in 
combination. Another test for this hypothesis was to analyze the expression of CA-biosynthesizing 
enzymes after treatment of PC12 cells with renalase, or its signaling peptide, RP-220. Following 
these treatments, no changes to the expression of CA-biosynthesizing enzymes were observed. If 
the hypothesis is correct, the anti-hypertensive effects of renalase may be downregulated in 
animals with elevated CA biosynthesis, like the SHR (Nguyen et al., 2009). Instead, renalase was 
upregulated at the mRNA level, and its protein level was regulated by other factors still to be 
determined. 
Because this study attempts to detect regulatory mechanisms of a novel gene, it is important 
to mention many small details that could have influenced our results. For example, no positive 
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control genes verified intracellular activity for PACAP, H2O2, Ang II, Epi, Nic, renalase, and RP-
220. PNMT mRNA levels from PACAP, Ang II, and Nic treatments were quantitated and showed 
high variability with no significant changes compared to controls. In other studies, these signal 
activators increased PNMT expression (Cahill et al., 2002; Evinger et al., 2005; Tai et al., 2010). 
It is unclear why these treatments did not induce PNMT upregulation as shown in other studies. 
Next, Epi induced a downregulation of TH and an increase in the inactive form of PNMT. It is 
likely that this effect is characteristic of Epi because of the abundance of inhibitory α2 receptors 
in PC12 cells (Moura et al., 2009). Downregulation of TH and upregulation of intron-retaining 
PNMT mRNA has not been previously shown before and it is unknown if these regulatory patterns 
can be used as a positive control of Epi signaling in PC12 cells. If further studies validate this 
signaling activity, intron-retaining PNMT mRNA could be used as a positive control of Epi 
signaling in the future. Of course, it is important to mention that renalase, RP-220, or H2O2 could 
not be verified for intracellular signaling activity without a proper positive control. Due to proper 
storage and handling, it is unlikely, but not guaranteed, that their degradation occurred over time. 
Other treatments including CoCl2 and Dex had some confirmation of signal activity, but not for all 
experiments. For example, CoCl2 activity was confirmed by nuclear HIF1α, but only in separate 
cells that were not analyzed for renalase expression. Finally, the use of pSer40 TH, although a 
good measurement of active TH, should have been performed on protein samples with the addition 
of sodium fluoride (NaF) in their extraction buffer. This addition would have decreased the activity 
of serine phosphatases (Sharma & Carew, 2002). Although an increase in pSer40 TH protein was 
observed after 24 hours (Figure 9D), this increase could have been due to different phosphatase 
activity between samples. In these cases of cell treatment where positive control genes were not 
completely analyzed, the unchanged renalase expressions could have been due to a lack of 
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intracellular activity. Unchanged renalase expression could also be due to the experimental design, 
which does not fully represent human physiology.  
Specifically, the use of PC12 cells could have hindered the analysis of renalase’s role in 
the adrenal medulla. As undifferentiated pheochromocytoma cells, their intracellular responses to 
the treatments of this study are slightly different than chromaffin cells (Qin et al., 2014).  
There are several reasons why the PC12 cell model could have prevented the detection of 
renalase expression changes. Renalase was previously shown to have higher expression in 
particular cancer cell types (Guo et al., 2016; Hollander et al., 2016). If renalase expression in 
pheochromocytoma cells is similarly upregulated, it could be that renalase transcription is 
consistently “switched on” with no ability for additional increases in mRNA. Because three 
established TFs that bind the renalase promoter (i.e. HIF1α, SP1, and STAT3) are all capable of 
being induced in PC12 cells, it is not likely that these TFs could consistently upregulate renalase 
(Tai et al., 2010; Y. Y. Wu & Bradshaw, 2000). If ZBP-89, which has not been fully analyzed in 
PC12 cells, has a low activity in this cell line, it could potentiate renalase transcription. In previous 
studies, it was shown that ZBP-89 can repress gene expression both independently, and through 
SP1 interaction (X. Zhang, Diab, & Zehner, 2003). Because a ZBP-89 binding site is located beside 
a SP1RE on the renalase promoter (Figure 7), downregulated ZBP-89 activity could increase 
renalase expression and reduce the range of renalase regulation. There is a possibility that ZBP-89 
is altered in PC12 cells because ZBP-89 is ultimately a tumour suppressor with pro-apoptotic 
effects (To et al., 2011). Being a cancer cell line, it is probable that tumour suppressors like ZBP-
89 are downregulated. Other putative binding sites in the renalase promoter could be responsible 
for consistent upregulation or downregulation (Sonawane et al., 2014). The putative homeobox 
protein B9 (HOXB9) binding site in the renalase promoter can sometimes be associated with the 
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repression of gene transcription (Sonawane et al., 2014; Wan et al., 2016). Interestingly, PC12 cell 
differentiation by NGF increases the expression of B-cell translocation gene protein 2 (BTG2), 
which has been shown to enhance HOXB9 promoter binding (el-Ghissassi et al., 2002; Prévôt et 
al., 2000). This increased HOXB9 activity by NGF could be another reason why the combined 
effects of PKA, PKC signaling, and cell differentiation did not induce changes in renalase 
expression. Other evidence that supports the idea of HOXB9 repression of renalase transcription 
is that estrogen increases HOXB9 transcription and female rats were found to have lower renal 
renalase mRNA levels (Appendix A). Therefore, any changes in BTG2 or HOXB9 in PC12 cells 
could alter the regulation of renalase from normal chromaffin cell physiology. PC12 cells could 
also affect renalase promoter activity via its putative E-box element (Sonawane et al., 2014). PC12 
cells do not express the E-box-binding TF, Max (Hopewell & Ziff, 1995). Although the particular 
renalase E-box sequence is not entirely specific to Max TFs, it is still possible that variable forms 
of Max activation bind to the renalase promoter (Adhikary & Eilers, 2005). Another mechanism 
that could consistently repress renalase expression is CpG island or histone methylation. 
Unfortunately, there is only a limited understanding of the epigenetic regulation of renalase. PC12 
cells could have a different intracellular localization of renalase compared to chromaffin cells as 
well. It has been shown that RPTs, but not podocytes or mesangial cells secrete renalase (F. Wang 
et al., 2012). Finally, if PC12 cells localize renalase differently than chromaffin cells, the 
regulation experiments in this study cannot be generalized to actual normal physiology. Also, all 
quantifications of renalase protein for objective 1 could have been underestimated by not 
accounting for secreted protein.  
 The use of the PC12 cell model could have prevented the effects of renalase or RP-220 
signaling as well. PC12 cells express the renalase receptor, PMCA4b, but levels of NOS are only 
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normally expressed after differentiation (Garcia, Usachev, Thayer, Strehler, & Windebank, 2001; 
Poluha et al., 1997; Sheehy et al., 1997). If renalase’s main intracellular signal is to alter NOS 
activity via PMCA4b, then the PC12 cell model would need to be differentiated before the effects 
of renalase could be detected. In contrast, chromaffin cells can express NOS, but only in certain 
subgroups of cells that secrete VIP and enkephalins (Heym, Colombo-Benckmann, & Mayer, 
1994). Therefore, renalase signaling in the adrenal medulla might only occur with these subgroups. 
However, it is still possible that other receptors of renalase exist that have yet to be identified. 
Another potential reason why renalase did not induce changes to CA biosynthesis is that its 
receptor’s expression and activity is lower in PC12 cells compared to chromaffin cells. It should 
also be considered that the recombinant renalase and the peptide used in this experiment were 
human. Because PC12 cells are derived from rats, potential surface receptors might not bind 
human renalase. Nevertheless, alignment of rat and human renalase reveals an amino acid 
similarity of 98%. This is one reason why human renalase, when administered to rats, still reduces 
circulating CA levels (H. T. Lee et al., 2013). If the primary receptor of renalase is PMCA4b, 
human renalase should still have signaling activity because both rat and human renalase have the 
necessary KKR sequence for receptor binding (L. Wang et al., 2014). Even with the presence of 
these signaling residues in our experiment, other experiments should confirm the effects of 
renalase in the adrenal medulla using other cell lines like bovine chromaffin cells.  
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5 – Conclusion 
To summarize, this study presents the first set of evidence that renalase is not part of an 
autocrine/paracrine negative feedback mechanism in the adrenal medulla. Out of the 10 signal 
activators that were used to analyze renalase expression, none of them resulted in a large change 
in renalase mRNA or protein levels. Renalase was also incapable of reducing the expression of 
CA biosynthesizing enzymes. Still, there could be signaling activity of renalase towards the 
adrenal medulla because of its regulation in vivo. Whether this regulation occurs in the adrenal 
cortex or medulla has yet to be determined. The details and contexts of these experiments indicate 
that our results can only be applied in a specific manner to the physiological systems of humans. 
This study has added plenty of new findings, but questions remain regarding renalase’s role in the 
adrenal medulla. If renalase does act upon the adrenal medulla, genetic or environmental changes 
to this process could be a new pathophysiological mechanism of hypertension. 
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6 – Future Directions 
 To add to the results of this experiment, several experiments can be performed. One helpful 
experiment would be to perform immunohistochemistry on the adrenal glands from WKYs and 
SHRs. With this method, the localization of renalase should be determined to confirm the findings 
in this experiment, and to see how renalase is regulated in the cortex and medulla. Another 
experiment that could be done is to use an ELISA-based catecholamine assay to detect changes in 
the cell media from renalase/RP-220-treated cells. From this method, it would first be necessary 
to confirm that CAs are upregulated by Dex. If this positive control is successful, it can be observed 
if renalase or RP-220 lower the levels of secreted CAs from PC12 cells (with or without Dex 
treatment). If renalase does lower CAs or protects against increased CAs, other methods should be 
performed to detect how this effect is achieved by renalase. For example, the membrane receptor 
(which may or may not be PMCA4b) should be confirmed, and intracellular pathways should be 
analyzed for activation. Because it is possible that renalase increases ROS regulation (by 
inactivating NAD(P)H isomers), ROS assays should be performed after a renalase treatment of 
PC12 cells as well. Particularly, levels of H2O2 and NO should be observed because of the 
mechanisms proposed by Beaupre et al. 2015 and Wang et al. 2015, respectively (Beaupre, Hoag, 
Roman, et al., 2015; L. Wang et al., 2015). Plenty of other cell signals should be used to treat PC12 
cells and determine if they alter renalase expression. Such cell signals include estrogen, because 
of the regulation shown in Appendix A, and cytokines, which may activate TFs that bind to the 
renalase promoter (i.e. STAT3; Y. Y. Wu & Bradshaw, 2000). Of course, it would be helpful to 
perform the cell treatments in this study in alternative cell lines like bovine chromaffin cells or the 
adrenocortical cell line, H295R. 
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As a newly discovered protein, more work should be done to understand the overall 
influence of renalase on normal physiology and pathophysiology. For instance, it is still unknown 
if renalase is secreted from all cell types. If renalase is not secreted from all cell types, an 
intracellular function should be established. Further, the role of renalase is still to be determined 
in tissues that strongly express renalase (e.g. the adrenal cortex and the glomerulus). Currently, 
there are no studies that have examined why renalase’s expression is remarkably higher in these 
tissues. To identify potential receptors of renalase in other cell types, cross-linking experiments 
followed by mass spectrometry can be performed as in L. Wang et al., 2015. There are many topics 
to be explored regarding renalase regulation too. These topics include regulatory mechanisms 
involving miRNAs, epigenetics, post-transcriptional processes, post-translational modifications, 
and putative promoter binding sites (e.g. validating the HOXB9 binding site). To conclude, the 
mystery of renalase remains and it is important for us to research these areas to reveal its potential 
uses in health and medicine.  
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8 – Appendix 
 
 
Figure A-1: Renalase (Rnls) mRNA levels in the kidney of adult male and female Wistar-Kyoto 
rats. RNA was extracted from coronal sections approximately 2mm thick through the hilus and 
homogenized with TRI Reagent. mRNA levels were detected by quantitative real-time RT-PCR 
(qRT-PCR) using a BioRad Chromo4 detector and Opticon 3 software. cDNA mastermixes were 
made using SensiFAST SYBR green Hi-ROX reagents as per the manufacturer’s instructions 
(FroggaBio). Fold-changes were compared to male rats using the 2^-ΔΔCt method. Renalase 
mRNA data were normalized to the GAPDH gene. Group means are presented along with their 
respective up and down standard errors (n = 4). ** indicates significance from males where p ≤ 
0.01 (using a two-tailed, unpaired t-test). 
 
 
 
